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Although existing kidney tissue engineering systems and cell-based strategies favoured 
significant advances in the field, they cannot reproduce the organ’s complex architecture. 
This prevented the use of these tissues in studying kidney development realistically, 
modelling diseases, and establishing therapeutic approaches. 
To fill these gaps, we devised a 3D engineering system for rapid generation of custom-
made geometrically predefined kidney units that more faithfully resemble their 
counterparts in vivo.  
Combining 3D printing and PDMS prototyping, we fabricated differently sized and shaped 
scaffolds into which MDCK cells were seeded and cultured under tubulogenic conditions. 
Cells grew and self-assembled into branched tubules with single lumen delimited by a 
polarised monolayered epithelium, exhibiting kidney-specific functions.  
To model polycystic kidney disease (PKD), we pharmacologically induced cyst formation 
within engineered tubules. Next, we tested and quantified different compounds’ effect on 
cyst regression, identifying new potential pharmacological treatment; we showed that 2-
deoxy-D-glucose is more effective than other compounds and discovered that berberine 
possesses high therapeutic potential for PKD treatment.  
Optimising the protocol and using different human iPSC lines, we successfully engineered 
functional human ureteric bud (UB)-like tubules capable of recapitulating early steps of 
UB morphogenesis. Exploiting these developmental capacities, we used tubules to identify 
a novel growth factor combination that induces budding events in a way comparable to 
mouse embryonic kidneys and that may therefore be involved in human UB development. 
Observing a marked reduction of ramified buds in tubules derived from a patient with 
heterozygous PAX2 mutation affected by focal segmental glomerulosclerosis, we 
speculated that such developmental disorder might have contributed to the patient’s 
condition.  
Overall, these findings document that our innovative and robust technology for controlled 
tubule engineering provides a valuable and reliable platform for kidney disease modelling, 
drug discovery and developmental studies, and may lay the groundwork for creating 
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1.1 Chronic kidney disease: a public health problem 
Chronic kidney disease (CKD) is a leading cause of morbidity and mortality in modern 
society. Currently, CKD affects hundreds of million people worldwide and has a consistent 
estimated global prevalence of between 11 to 13% (Hill et al., 2016). Its global incidence 
and prevalence are rapidly increasing, particularly in developing countries, thus making 
CKD, without a doubt, a major global public health issue.  
Major causes of CKD are diabetes, hypertension, infectious diseases and acute kidney 
injury as consequence of several drug exposure, and polycystic kidney disease (PKD), the 
most common genetic renal disease affecting all ethnic groups (Ong et al., 2015; Brunelli 
et al., 2015; Mao et al., 2016). 
In most patients, CKD eventually progress towards kidney failure, also called end-stage 
renal disease (ESRD) that, being characterised by irreversible loss of nephrons and 
deterioration of renal function, is incurable.  
The only treatment for ESRD is renal replacement therapy (RRT), which aims to 
substitute the critical kidney functions and sustain life in affected people. RRT consists of 
hemodialysis, peritoneal dialysis and kidney transplantation.  
Although dialysis keeps patients alive by replacing exclusively the non-endocrine kidney 
functions such as removal of molecular waste products from the blood, the patients’ quality 
of life is severely impaired by life-threatening complications (Rodrigues-Díez et al., 2017). 
The global healthcare costs for dialysis patients are between $150,000 and $200,000 per 
year and will exceed $1 trillion this decade. This significant economic burden, combined 
with the ongoing 7% annual increase in patients who need dialysis, will make this 
treatment impractical and unaffordable even in developed countries (Perico and Remuzzi, 
2012).  
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The alternative to dialysis is kidney transplantation, which, at present, represents the most 
effective treatment for patients with ESRD. In fact, both quality of life and life expectancy 
in people who underwent kidney transplantation are better than in long-term dialysis 
patients (Wolfe et al., 1999). Unfortunately, almost every patient who receives kidney 
transplant undergoes non-specific immunosuppressant treatments, with increased risk of 
developing malignancies, opportunistic infections, cardiovascular and metabolic diseases, 
all of which negatively influence graft function and outcome. In addition to these 
problems, the critical shortage of compatible donor organs for transplantation makes it 
extremely hard to meet the existing demand for renal replacement, so that the vast majority 
of patients die on the waiting list before receiving a kidney (Rodrigues-Díez et al., 2017).  
The high costs associated with RRT, combined with the rising imbalance between the 
number of patients waiting for kidney transplantation and the availability of donor organs, 
make indispensable the development of alternative therapeutic approaches. The 
establishment of effective therapies for CKD is also hindered by the lack of experimental 
models systems that faithfully reproduce the disease and the kidney’s extremely complex 
cellular composition, intricate anatomy and physiology.  
 
1.2 Early kidney development 
The posterior primitive streak, a linear band of cells that forms at the caudal edge of the 
embryo epiblast, gives rise to the intermediate mesoderm (IM), a narrow cell population 
comprised between paraxial and lateral plate mesoderm, from which mammalian kidney 
originates. The IM differentiates, in turn, into the nephric duct (ND) epithelium and the 
adjacent metanephric mesenchyme (MM), the two key renal precursor tissues that will 
form the metanephric kidney through reciprocal and finely orchestrated interactions 
(Saxén, 1987; Little et al., 2016; Takasato et al., 2016) (Figure 1).   
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In mice, at 10.5 embryonic days (E10.5), and E35 in humans, morphogenetic signals from 
the MM induce the outgrowth of the ureteric bud (UB) as a lateral branch at the caudal end 
of the ND epithelium. The UB is a tubular structure endowed with a lumen delimited by a 
polarised epithelium and a basement membrane (Meyer et al., 2004; Chi et al., 2009). UB 
formation occurs in correspondence of a single area, so that only one UB arises from the 
ND, thus guaranteeing the development of a single and unique collecting duct system. The 
UB stalk between the MM and the ND epithelium develops into the ureter that joins the 
kidney with the bladder. 
At E11, the UB invades the adjacent MM and, through direct cell-cell contact and secretion 
of morphogens by its cells, induces the condensation of a subset of MM cells surrounding 
the bud tip. These condensed mesenchymal cells form the cap mesenchyme (CM), which 
comprises nephron progenitor cells morphologically distinguishable from the surrounding 
un-induced metanephric blastema (Davidson, 2008) (Figure 1). 
At E11.5, the CM induces the UB epithelium to branch for the first time and generate a T-
shaped bifurcation consisting of two UB tips, each at the end of a stalk. Concomitantly, the 
newly formed UB tips induce condensation of surrounding un-induced MM cells, leading 
to the formation of a CM in correspondence of each bud tip (Vainio and Lin, 2002; Hendry 
et al., 2011; Krause et al., 2015). From this time onwards, each CM will induce the UB 
tips to branch and, simultaneously, undergo mesenchymal-to-epithelial transition (MET) to 
form a primitive polarised epithelium, the renal vesicle (RV). The RV grows, elongates 
and forms a comma-shaped body, which then develops into an S-shaped body that 
undergoes segmentation and eventually gives rise to the nephron (Figure 1). In particular, 
the S-shaped body’s distal portion, which fuses to a UB branch, becomes the distal tubule 
of the nephron, the middle region gives rise to both the loop of Henle and the proximal 
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tubule of the nephron, and the other end develops its own vascularisation to form the 
glomerulus (Davidson, 2008).  
As kidney development proceeds, the UB epithelium continues to grow, elongate and 
branch, with each new UB tip acting as an inductive centre for nephrogenesis (Vainio and 
Lin, 2002). Through its developmental program, named branching morphogenesis, which 
consists of iterative budding and branching events, the UB eventually forms the tree-like 
collecting duct system of the kidney with the typical cortical-medullary organisation. 
These MM and UB derivatives will develop a network of interconnected epithelial tubules 
consisting of polarised monolayered epithelia of aligned and tightly adhering cells 
surrounding a single central lumen. This complex structural organisation arises through the 
formation of specialised junctions between cells, which establish apical domains oriented 
toward the lumen, and basal and lateral domains in contact with the basement membrane 
and adjacent cells, respectively (Andrew and Ewald, 2010). In order to assemble into 
appropriately polarised tissue, cells must also interact with the extracellular matrix (ECM) 
through different types of receptors, such as integrins, and with neighbouring cells through 
diffusible molecules, such as morphogens, chemoattractants and chemorepellants (Bryant 
and Mostov, 2008; Bryant et al., 2010). Therefore, the combination of cell-cell and cell-
ECM interactions drives the apical-basal polarity establishment by segregating membrane 
components into different cell domains.   
As every epithelial tubular structure, kidney epithelial tubules can form through the 
mechanisms of cord hollowing, cell hollowing and cavitation (Andrew and Ewald, 2010; 
Lubarsky and Krasnow, 2003).  
In cord hollowing, small multiple lumens form at the apical membrane contact sites - 
following cell polarity establishment within tissue primordia - and then fuse together to 
create a single and continous lumen.  
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In cell hollowing, luminal spaces originate within individual cells as large cytoplasmic 
vesicles, which then fuse together and, ultimately, with the plasma membrane to connect 
with lumens formed within the adjacent cells of the developing tubular epithelium.  
The mechanism of cavitation begins with polarisation of unpolarised primordia’s 
peripheral cells that will constitute the mature tubular epithelium, followed by death for 
apoptosis of the cells in the central region that are not in contact with the ECM, leading to 
the generation of a single lumen.  
Kidney tubules are surrounded by supporting cells, also known as stromal cells, which 
originate from the MM and constitute a population of cells distinct from that of the 
nephrogenic precursors (Figure 1). Shortly after UB invasion, stromal cells can be 
identified in the MM as spindle-shaped mesenchymal cells (Hatini et al., 1996). Stromal 
progenitor cells can differentiate into various non-epithelial cells in the adult kidney, 
including interstitial fibroblasts responsible for synthesizing collagen and producing 
erythropoietin (Bachmann et al., 1993; Li et al., 2014; Maxwell et al., 1993), endothelial 
cells that form the peritubular capillaries (Sims-Lucas et al., 2013), vascular smooth 
muscle cells, pericytes and glomerular mesangial cells (Humphreys et al., 2010). 
Furthermore, by secreting ECM proteins and signalling molecules, stromal cells play 
pivotal roles for the appropriate nephrogenesis and collecting duct system formation. In 
particular, stromal cells are involved in regulating MM epithelialisation, UB growth and 
branching morphogenesis, and, by antagonising inductive signals from MM, in inhibiting 
budding from inappropriate or multiple sites of the ND epithelium (Al-Awqati and Oliver, 
2002; Cullen-McEwen et al., 2005). 
Overall, cell populations and tissues described above interact in a spatiotemporally 
regulated manner to develop an intricate architecture, which supports the functional and 
physiologically active adult kidney. 
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1.3 Overview of kidney anatomy and functions 
The kidney is a vital organ with an exceptionally complex morphology and highly 
specialised in maintaining body fluid homeostasis. Indeed, by filtering blood, kidney 
regulates the body’s water balance and chemical composition, controls levels of 
electrolytes and metabolites, and removes metabolic waste products to finally produce and 
excrete urine. Additional major kidney functions are reabsorption of essential nutrients, 
regulation of blood volume and pressure, and production of hormones indispensable for 
regulating erythropoiesis and the bones’ density.  
 
1.3.1 Kidney anatomy 
In vertebrates, kidneys are two bean-shaped organs located on the left and right sides of the 
body retroperitoneal space. Each kidney shows a convex and a concave side. The narrow 
opening on the concave side, through which the renal artery enters the kidney and the renal 
vein and the ureter leave, is called renal hilum. A thin layer of connective tissue, known as 
the renal capsule, envelopes the whole kidney’s surface (Rodrigues-Díez et al., 2017) 
(Figure 2). Beneath the renal capsule, the kidney can be divided in two main regions easily 
recognisable by observing the sagittal section of the organ: (i) the renal cortex on the 
outside, and (ii) the deeper medullary region (Taal et al., 2011). In humans, the medulla is 
organised into 8 to 18 cone-shaped structures, the renal pyramids, spaced out by 
projections of the cortex, called renal columns. The base of each renal pyramid resides 
within the renal cortex, while its tip, the papilla, extends inward towards the renal pelvis, 
and empties the urine formed by each pyramid into a minor calyx (Figure 2). The minor 
calyces coalesce to form 2 to 3 major calyces, which in turn fuse to form the renal pelvis - 
a funnel-like structure that exits the kidney through the renal hilum and drains the urine 
away into the ureter (Taal et al., 2011). Renal pelvis, calyces and hilum are contained into 
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a fatty compartment, the renal sinus, which separates these structures from the renal 
medulla (Figure 2). This structural organisation is crucial to the appropriate kidney 
function since it establishes an osmotic gradient from the cortex to the medulla that drives 
urine concentration.  
 
1.3.2 The nephron  
The nephron is the key structural and functional unit of the kidney. It filters blood and 
produces urine. Structurally, it can be subdivided in two main sections: (i) the renal 
corpuscle, needed for blood filtration, and (ii) the renal tubule, needed for reabsorption and 
secretion (Rodrigues-Díez et al., 2017).  
The renal corpuscle is composed of glomerulus, mesangium and Bowman’s capsule 
(Figure 3). The glomerulus is a tuft of capillaries (or capillary loops) surrounded by 
mesangial cells, and is located between an afferent arteriole, which supplies blood to the 
glomerulus, and an efferent arteriole, which drains blood away from the glomerulus. The 
region where renal arterioles enter and leave the glomerulus is called vascular pole. The 
Bowman’s capsule envelops the glomerulus and consists of an inner layer of specialised 
epithelial cells, called podocytes, and an outer epithelial layer of parietal cells. The narrow 
cavity between these two epithelial layers is the Bowman’s space, also known as urinary 
space. Podocytes are extremely specialised cells characterised by interdigitating foot 
processes wrapped around the glomerular capillary loops, and forming cell-cell junctions 
termed slit diaphragms. The latter are crossed by pores with heterogeneous size and shape, 
which are responsible for the selective passage of macromolecules (Gagliardini et al., 
2010). The Bowman’s capsule connects to the renal tubule, which can be subdivided in 
three segments: (i) the proximal convoluted tubule, lined by a simple cuboidal epithelium 
of cells with brush borders that strongly increase the absorption surface; (ii) the loop of 
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Henle, a U-shaped epithelial conduit consisting of two portions: the descending limb and 
the ascending limb; (iii) the distal convoluted tubule that drains urine into the collecting 
duct via the connecting tubule (Figure 3). The human kidney contains up to 1.5 million 
nephrons, each of them spans the renal cortex and medulla. Specifically, the renal cortex 
contains glomeruli, proximal and distal convoluted tubules, and the first trait of the 
collecting ducts; the renal medulla contains both the loops of Henle and the collecting 
ducts. Since the collecting duct system’s initial portion is located in the renal cortex, 
whereas the rest extends inwards, towards the renal medulla, it is characterised by cortical-
medullary orientation (Figure 3).  
The fact that both nephron and collecting duct epithelia consist of cells with well-defined 
morphological and functional properties, explains why they are competent at exerting 
diverse and specific physiological roles. 
 
1.3.3 Kidney functions 
The kidney is responsible for regulating body fluids’ composition and volume by filtering 
the blood to eliminate metabolic waste products, such as creatinine, ammonia, urea, uric 
acid, and toxins, and by reabsorbing water and essential nutrients. Blood filtration begins 
in the glomerulus and leads to the production of urine (Rodrigues-Díez et al., 2017). The 
filtration barrier that divides blood and Bowman’s space consists of the fenestrated 
monolayered endothelium lining glomerular capillaries, the glomerular basement 
membrane, and the slit diaphragm’s pores between the interdigitated foot processes of the 
podocytes enveloping the capillary tuft (Haraldsson et al., 2008).  
In physiological conditions, only molecules of lower molecular size than albumin (68 
kDa), for instance water and small molecules, can pass through this filter and reach the 
Bowman’s space, forming the glomerular ultrafiltrate. The latter, flows through the 
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sequential segments of the renal tubule where it is modified by the highly regulated 
processes of reabsorption and secretion. In fact, together with waste and toxic products, the 
ultrafiltrate also contains metabolically useful solutes that require reabsorption.  
Most of the ultrafiltrate reuptake (65-70%) occurs in the proximal convoluted tubule and 
allows water, electrolytes, amino acids, glucose, vitamins, and other essential 
macromolecules to come back to the bloodstream through peritubular capillaries. 
Additional ultrafiltrate concentration takes place along the loop of Henle’s descending and 
ascending limbs via water, sodium and other ions reabsorption. This process results from 
the osmotic difference existing between the hypotonic ultrafiltrate and the hypertonic 
medullary interstitium (Rodrigues-Díez et al., 2017).  
As the ultrafiltrate passes through the distal convoluted tubule, reabsorption of sodium 
chloride, calcium and magnesium, and secretion of potassium takes place (Subramanya 
and Ellison, 2014). This is followed by further acidification of the ultrafiltrate since water 
and bicarbonate are reabsorbed as it passes from the distal convoluted tubule to the 
medullary collecting duct. Once at the end of the collecting duct, in the renal papilla, the 
modified ultrafiltrate, now called urine, is composed exclusively of a minimum amount of 
water and non-reabsorbed compounds, reaching the renal pelvis to be finally drained away 
to the bladder through the ureter.   
In virtue of these sophisticated mechanisms, kidneys play a central role in the regulation of 
water and electrolyte homeostasis, and blood pH level and pressure. Kidneys can also 
regulate blood pressure through the production of the proteolytic enzyme renin secreted by 
the juxtaglomerular cells of the juxtaglomerular apparatus located between the glomerular 
vascular pole and the distal convoluted tubule of the same nephron. By triggering the 
renin-angiotensin system, a hormonal cascade that exerts the homeostatic control of arterial 
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pressure, renin raises blood pressure in response to hypotension (Rodrigues-Díez et al., 
2017). 
In virtue of its ability to synthesize and secrete hormones, the kidney also exerts multiple 
endocrine functions. The two main hormones produced by kidney are erythropoietin and 
calcitriol. The first is a glycoprotein secreted by the peritubular cortical interstitial 
fibroblasts that stimulates red blood cell production in response to anemia. The second is 
the biologically active form of vitamin D produced by the proximal convoluted tubular 
cells. Calcitriol has been shown to be involved both in suppression of renin production and 
in maintenance of calcium homeostasis by regulating calcium reabsorption in distal 
convoluted tubules and medullary collecting ducts (Freundlich et al., 2008; Wang et al., 
2012).  
 
1.4 Engineering approaches to regenerate the kidney 
Many investigation groups aimed at creating 3D kidney tissue ex vivo by exploiting the 
MM and UB cells’ innate ability to reciprocally interact and instruct each other, as well as 
the mouse embryonic kidney’s capacity to reconstruct itself after single-cell dissociation 
and reaggregation. Specifically, these studies - overviewed in the following paragraphs and 
summarised schematically in Figure 4 - employed embryonic kidney fragments and renal 
progenitor cells obtained either from rodent embryonic kidneys or human pluripotent stem 
cell (hPSC) directed in vitro differentiation. 
 
1.4.1 Tissue-based approaches 
The pioneering studies by Grobstein, dated early 1950s, demonstrated that MM and UB 
tissues could be grown ex vivo and partially recapitulate the kidney’s developmental 
program, giving rise to nephron formation and collecting duct branching morphogenesis, 
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respectively (Grobstein, 1953). Based on such discoveries, other groups co-cultured 
isolated intact MM with various inductors in order to attain nephrogenesis in vitro (Ekblom 
et al., 1981; Barasch et al., 1996). Specifically, isolated intact MM grew and matured into 
glomerular and renal tubular epithelia when cocultured with exogenous embryonic spinal 
cord explants used as nephrogenesis inductors (Ekblom et al., 1981). In another study, 
Barasch et al. showed that isolated MMs could be induced to undergo nephrogenesis when 
cultured in direct contact with UB cell pellets, without the need of spinal cord or any other 
exogenous tissues (Barasch et al., 1996).   
With regard to UB branching morphogenesis, it was demonstrated that uninduced intact rat 
UB isolated from surrounding MM could undergo branching morphogenesis in a 3D 
culture system (Qiao et al., 1999a). Specifically, UB was embedded in ECM-mimicking 
gel, and cultured in conditioned medium from an E11.5 mouse MM-derived cell line (BSN 
cells), which was supplemented with glial cell line-derived neurotrophic factor (GDNF) 
(Qiao et al., 1999a). This molecule is expressed by the MM during the early stage of 
kidney development and is essential for UB formation, growth and morphogenesis (Sainio 
et al., 1997). Under these culture conditions, the UB developed into 3D polarised and 
extensively branched epithelial tubular structures endowed with a single lumen, without 
the need of direct contact with MM tissue. These branched tubular structures were capable 
of inducing nephrogenesis when recombined with E13.5 rat MMs in vitro. Remarkably, 
MM-derived nascent nephrons were connected to the UB tubular structures to form a 
continous lumen, and, in turn, UB responded to the morphogenetic inductive effects of the 
adjacent MM by further growing and extending branches into the MM tissue. These data 
demonstrated that (i) UB branching morphogenesis does not require direct contact with 
MM, (ii) the in vitro-derived branched tubular structures retain their intrinsic ability to 
induce nephrogenesis as occurs in vivo, and (iii) the regulation of branch elongation, as 
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well as the appropriate branching pattern establishment, take place only when UB was 
physically combined in vitro with MM (Qiao et al., 1999a).  
This 3D culture system was also used to propagate isolated rat UBs in vitro (Steer et al., 
2002). The isolated intact UBs were cultured and induced to undergo branching 
morphogenesis, then after 8 days of culture were subdivided into thirds and each portion 
cultured independently for additional 8 days. This process was repeated for several UB 
generations. Of note, propagated UBs recombined with freshly isolated MMs were able to 
induce nephrogenesis and retained the ability to connect with the MM-derived tubules, 
leading to the formation of ‘neokidneys’ containing tubular structures comparable to those 
of whole rat embryonic kidney cultures (Steer et al., 2002). Building on this strategy, 
Rosines et al. devised an approach that sequentially induced an isolated ND to bud and 
branch in vitro, demonstrating that the capacity to undergo branching morphogenesis in 
vitro is not retained exclusively by the UB (Rosines et al., 2007). When freshly isolated 
MM was recombined with a ND-derived branched structure, the 3D nephron formation 
occurred, similarly to that obtained in UB-derived branched tubular structures and MM 
recombination experiments. The MM derivatives appeared phenotypically normal, 
expressed tubular transporters and were capable of organic ion transport, all features 
demonstrating maturation and functional capacity of the recombined tissue. Moreover, 
when the recombined kidney-like tissue was implanted beneath the renal capsule of a rat 
host, it developed multiple glomeruli positive for endothelial markers and containing 
erythrocytes. Finally, through global gene expression pattern analyses, it was demonstrated 
that the transcriptome of the nephron structures that had developed within the recombined 
tissue bore a resemblance to the transcriptome of the E18 rat kidney (Rosines et al., 2007).  
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1.4.2 Creating 3D kidney tissue using embryonic kidney cells and cell lines 
One of the most promising approaches in the field of tissue engineering is the generation of 
‘foetal’ organs by exploiting the progenitor cells’ intrinsic capacity to organise themselves 
into 3D structures typical of early organogenesis (Xinaris et al., 2015).  
Traditional reaggregation experiments revealed that embryonic kidney cells are able to 
differentiate and self-organise to form 3D tubular structures. In these pioneering studies, 
Auerbach and Grobstein developed a method for in vitro generation of a 3D tissue 
containing rudimental nephron-like structures through MM dissociation into single cell 
suspensions followed by reaggregation and co-culture onto embryonic dorsal spinal cord 
cell layer (Auerbach and Grobstein, 1958). Other early studies focused on kidney tissue 
generation via cell-based strategies demonstrated that adult renal epithelial cell lines, 
cultured in ECM gel-based 3D culture systems, could undergo tubulogenesis in the 
presence of conditioned media or embryonic kidneys (Montesano et al., 1991a, 1991b; 
Steer and Nigam, 2004)  
These studies showed that when Madin-Darby canine kidney (MDCK) cells and murine 
inner medullary collecting duct (mIMCD3) cells were embedded in ECM gel and cultured 
with fibroblast-conditioned medium (Montesano et al., 1991a, 1991b) or with embryonic 
kidneys in the absence of direct contact (Santos et al., 1994; Barros et al., 1995) underwent 
branching tubulogenesis.  
Using a similar approach, Machiguchi and Nakamura implanted individual tubular 
epithelial cells and mesenchymal stem cells into the subcutaneous spaces of 
immunodeficient rats, and stimulated them with a combination of vascular endothelial- and 
tubular cell-derived conditioned media to form glomerular and renal tubular structures 
(Machiguchi and Nakamura, 2013).  
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A step forward was made through the derivation and in vitro propagation of immortalised 
cell lines from uninduced MMs (BSN cell line) and unbranched UBs, which were isolated 
from E11.5 mouse embryonic kidneys (Sakurai et al., 1997). Using these cells, Sakurai et 
al. developed a method for establishing a tubulogenesis system in vitro. In particular, the 
authors reported that, when cultured in a 3D ECM-gel with BSN cell-conditioned medium, 
UB cells formed cell processes and then multicellular cord-like structures - morphogenetic 
changes peculiar of early in vitro branching tubulogenesis. The multicellular cord-like 
structures eventually branched and gave rise to ramified and polarised epithelial tubular 
structures endowed with lumen comparable to those observed in cultured intact embryonic 
kidneys.  
A more recent in vivo study showed that MM and UB cell lines cocultured in 3D matrices 
and implanted in immunodeficient mice, organised into spheroid and tubuloid structures 
that matured to finally form epithelia with lumens surrounded by capillary-like structures 
(Velagapudi et al., 2012). In particular, UB cells formed almost exclusively the tubuloid 
structures and expressed UB/collecting duct markers, whereas MM cells differentiated 
mainly into capillary-like cells. Although the tubuloid structures exhibited specialised 
epithelial features such as apical vacuoles, microvilli, junctional complexes and linear 
basement membranes, the formation of brush borders and the expression of aquaporin 1 - 
features of mature proximal tubular epithelium - were not observed (Velagapudi et al., 
2012).  
In the last decade, several groups showed that kidney tissue could be generated using 
single cells freshly isolated from embryonic kidneys as starting material (Osafune et al., 
2006; Unbekandt and Davies, 2010; Xinaris et al., 2012; Ganeva et al., 2011; Xinaris and 
Yokoo, 2014).  
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By modifying previous culture protocols (Grobstein, 1953; Kispert et al., 1998), Osafune 
et al. demonstrated that murine E11.5 MM progenitor cells strongly expressing Sall1 - a 
zinc-finger nuclear transcription factor expressed in the MM and essential for kidney 
development (Nishinakamura et al., 2001) - generated 3D colonies when cultured onto a 
feeder layer of a mouse embryonic fibroblast cell line stably expressing Wnt4, a 
glycoprotein required to trigger nephrogenesis in isolated MM (Kispert et al., 1998; 
Osafune et al., 2006). The colonies reconstituted a 3D kidney tissue consisting of 
glomerular- and tubular-like structures positive for the podocyte marker Wilm’s tumor 1 
(WT1) and the proximal tubule marker Lotus tetragonolobus lectin (LTL), respectively 
(Osafune et al., 2006). Although functional features of these structures were not 
investigated in vivo, this bioengineering approach suggested that rudimental 3D kidney 
tissues could be obtained from single cell suspensions.  
Building on Grobstein’s group studies (Grobstein, 1955; Auerbach and Grobstein, 1958), 
Unbekandt and Davies set up a novel method to generate 3D embryonic kidney tissue 
through E11.5 mouse kidneys dissociation into single cell suspensions followed by 
reaggregation, without the need for any exogenous tissue (Unbekandt and Davies, 2010). A 
key innovation of this method was the transient culture (for the first 24 hours) of the cell 
reaggregates with a Rho-associated kinase inhibitor in order to enhance cell self-
organisation and UB branching reactivation, and prevent cell death for apoptosis, which is 
due to the dissociation process (Schmidt-Ott, 2010; Unbekandt and Davies, 2010). Even 
though this protocol allowed the engineering of embryonic kidney tissue containing 
nephrons at different developmental stages and with normal anatomies, the UB developed 
as a multitude of small individual collecting duct trees, rather than a single highly branched 
UB/collecting duct tree, as normally occurs during kidney organogenesis. Furthermore, 
this would mean that, assuming that the tissue were vascularised and physiologically 
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active, the multiple individual collecting ducts would not be effective for draining urine 
away towards a common exit. To overcome the above limitation, the authors refined the 
system by culturing, for 3-4 days, MM cell reaggregates in combination with a single 
reformed UB dissected from a reaggregated tissue of a previous round of dissociation-
reaggregation. This manoeuvre led to the engineering of 3D embryonic kidney tissue 
containing immature nephrons directed outwards and each distally connected to a branch 
of the single UB-derived collecting duct tree. Such configuration resembled the normal in 
vivo kidney tissue patterning (Ganeva et al., 2011).  
Although the dissociated and reaggregated MM (drMM) maintains its nephrogenic 
potential, if nephrogenesis is induced following the dissociation step, drMM degenerates 
and undergoes apoptosis (Koseki et al., 1992; Saxén, 1987). To address this problem, a 
novel protocol that allows drMM to maintain its nephrogenesis competence ex vivo has 
been recently developed (Junttila et al., 2015). In particular, drMM was cultured in the 
presence of bone morphogenetic protein 7 (BMP7) and fibroblast growth factor 2 (FGF2) - 
both showed to promote the survival of isolated intact MM - for 24 hours before nephric 
tubule induction (Junttila et al., 2015). As a result, when cultured onto the dorsal piece of 
an E11.5 embryonic spinal cord as inducer of tubulogenesis, the uninduced drMM cells 
survived and assembled into segmented nephrons expressing markers of glomerular 
podocytes, proximal and distal tubules, and ascending loop of Henle. Furthermore, to 
evaluate potential for kidney organogenesis in vitro, the BMP7/FGF2-treated MM cell 
reaggregates were combined with one freshly isolated intact UB, which was previously 
stimulated with GDNF, to form explants. After 9 days, explants displayed a unique 
branching UB, multiple developing nephrons around the UB tips, and renal corpuscle-like 
structures, as occurs during normal kidney organogenesis. Consequently, the major 
advantage of this novel protocol for kidney tissue engineering was the extension of the in 
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vitro culture time of the uninduced drMM, which in the above-mentioned culture 
conditions survived and maintained its nephrogenic potential with no sign of apoptosis 
(Junttila et al., 2015). 
Despite the advances in the field, none of these cell-based strategies has favoured the 
development of vascularised glomeruli with appropriately structured glomerular filtration 
barrier, due to the avascular in vitro environment. Hence, this important impediment to the 
generation of mature and functional kidney tissue from renal progenitor cell suspensions 
persisted. 
In order to overcome this obstacle, our group, building on previously reported technologies 
(Auerbach and Grobstein, 1958; Unbekandt and Davies, 2010), generated kidney 
organoids in vitro and implanted them into living recipients. Once in vivo, organoids 
further grew and matured, developing vascularised glomeruli and functional nephrons 
(Xinaris et al., 2012). Specifically, organoids were constructed using single cell 
suspensions of fully dissociated E11.5 mouse kidneys and, after growing in vitro for 5 days 
- the time they develop elongating tubular profiles with distal poles connected to the 
adjacent branching UB/collecting duct epithelia - they were implanted below the renal 
capsule of unilaterally nephrectomised athymic rats. The unilateral nephrectomy - a 
surgical intervention known to enhance the expression of several mitogenic, prosurvival, 
and morphogenic genes in rodents (Siegel et al., 1996; D’Agati, 2012) - was performed to 
promote growth and maturation of the grafted tissue.  
Two pivotal steps introduced with this optimised reaggregation method were the 
generation of kidney organoids as large cell aggregates to allow survival and growth of the 
implanted tissues in vivo and, to promote endogenous vascular development, their 
pretreatment with vascular endothelial growth factor (VEGF) before implantation, 
followed by systemic VEGF injections into the host animals. This second manoeuvre 
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restored the podocyte-endothelial cell stimulation mediated by VEGF, which drives the 
formation of glomerular capillary loops (Kitamoto et al., 1997, 2002; Tufro et al., 1999; 
Guan et al., 2006). Indeed, during kidney development, endothelial progenitor cells 
residing in the renal stroma express VEGF receptors and migrate into the vascular cleft of 
developing glomeruli - where they will form the glomerular capillary loops - in response to 
podocyte secretion of VEGF (Dressler, 2006; Jeffrey and Miner D.R.A., 2012).  
As a result, the implanted organoids grew, became vascularised, and developed glomeruli 
with fenestrated capillaries and fully differentiated podocytes having foot processes spaced 
by slit diaphragms (Xinaris et al., 2012). Furthermore, implanted tissues exhibited basic 
kidney-specific functions, including capacity for proximal tubular reabsorption of 
systemically injected labelled macromolecules that reached tubular lumen by 
transglomerular passage, and production of erythropoietin by stromal cells when recipient 
animals were made anaemic (Xinaris et al., 2012). More in-depth investigations combining 
electron microscopy analysis and macromolecular tracing experiments revealed that, in 
vivo, the organoids recapitulated the extremely complex 3D structural framework of the 
glomerular slit diaphragm, and performed selective glomerular filtration and tubular 
reabsorption (Xinaris et al., 2015).  
The organoid system is a reliable tool to validate the renal differentiation potential of 
human stem cells from different sources. By using this technology, several groups 
determined the human stem cells’ capacity to follow renal developmental program and 
their contribution to developing kidney compartments (Siegel et al., 2010; Papadimou et 
al., 2015; Xinaris et al., 2016). Siegel et al. showed that, when mixed with suspension of 
mouse embryonic kidney cells and reaggregated to form 3D chimeric organoids, human 
amniotic fluid stem cells (hAFSCs) integrated into developing kidney structures positive 
for PAX2 - a marker expressed in UB and developing nephrons (Rothenpieler and 
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Dressler, 1993) - and calbindin - a specific marker for UB and distal tubules (Siegel et al., 
2010) -  wherein they also started to express both markers.  
More recently, our group applied the optimised technology described above (Xinaris et al., 
2012) to generate 3D chimeric organoids from E11.5 mouse kidney cells and hAFSCs that 
were genetically modified to express GDNF (Xinaris et al., 2016; Benedetti* et al., 2016) 
in order to enhance their contribution to developing nephrons (Yokoo et al., 2005). This 
manipulation promoted hAFSCs integration in the caps of condensing MM positive for 
neural cell adhesion molecule (NCAM) - a specific marker of condensed MM (Bard et al., 
2001) - and PAX2 (Xinaris et al., 2016). When implanted beneath the renal capsule of 
athymic rats, chimeric organoids grew, developed tubular structures and glomeruli that 
contained red blood cells, thus revealing the establishment of vascular connection between 
host and graft. In the implanted tissues, the majority of hAFSCs incorporated in glomerular 
structures, and differentiated into mature podocytes endowed with interdigitating foot 
processes separated by well-formed slit diaphragms (Xinaris et al., 2016). Remarkably, the 
hAFSC-derived podocytes displayed active endocytosis of systemically injected 
fluorescent bovine serum albumin (BSA), a functional feature typical of normal podocytes 
in vivo (Eyre et al., 2007). 
This chimeric organoid system have been also applied by our group to validate renal 
differentiation and integration potentials of various cell types, such as the HK2 renal 
proximal tubular epithelial cell line, human bone-marrow mesenchymal stem cells (hBM-
MSCs), and hBM-MSC-derived proximal tubular-like epithelial cells (Papadimou et al., 
2015; Benedetti* et al., 2016). The latter cell type (CL17) was generated by direct hBM-
MSC reprogramming using HK2 cell extracts. In 1-day chimeric aggregates, CL17 cells 
incorporated into the condensing MM. At 5 days, both CL17 and HK2 cells formed 
chimeric elongating tubular structures adjacent to early glomerular-like structures. 
 CHAPTER 1 - INTRODUCTION 
21 
 
Otherwise, hBM-MSCs did not form or contribute to renal structures, thus indicating 
neither nephrogenic nor integration potential (Papadimou et al., 2015).  
 
1.4.3 Creating 3D kidney tissue from pluripotent stem cells 
Pluripotent stem cells (PSCs) are able to self-renew indefinitely in vitro while maintaining 
the capacity of differentiating into specialised derivatives of all the three primary germ 
layers (Yu and Thomson, 2008). Due to these characteristics, human PSCs (hPSCs) 
emerged as an extremely valuable source for studying human development, modelling 
disease, testing drugs, and establishing strategies aimed at engineering human tissues in 
vitro. The hPSCs are classed as human embryonic stem cells (hESCs), which derive from 
the inner cell mass of a blastocyst (Thomson et al., 1998), and human induced pluripotent 
stem cells (hiPSCs). The latter have been generated by the Shinya Yamanaka’s group, first 
from mouse (Takahashi and Yamanaka, 2006) and then from human (Takahashi et al., 
2007) somatic cell reprogramming. Specifically, the authors induced adult terminally 
differentiated donor cells to revert to a pluripotency state by transfection of four selected 
transcription factors (OCT4, KLF4, SOX2 and c-myc). The hiPSCs possess morphology, 
proliferation capacities and differentiation potential highly comparable to hESCs and, as 
their generation does not entail destruction of human embryos, they allow circumventing 
all ethical issues associated with the use of hESCs. Importantly, hiPSCs, which can be 
derived from both healthy people and patients, are, accordingly, immunocompatible with 
the original donor, thus avoiding the need for immunosuppressants when transplanted back 
into the donor organism. For all these reasons, the discovery of hiPSCs gave way to a new 
era in stem cell biology and regenerative medicine, creating significant prospects for the in 
vitro generation of renal progenitor cells as source for engineering immunocompatible 
kidney tissue applicable to transplantation. 
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In the last few years, intense research has been dedicated to develop protocols for 
differentiating hPSC towards specific renal progenitor cell types.  
Mae et al. differentiated hPSCs (both hESCs and hiPSCs) towards IM cells (Mae et al., 
2013) in a stepwise fashion. Initially, hPSCs were stimulated with Activin A and the Wnt 
agonist CHIR99021 for 3 days to differentiate into mesoderm, and then were treated with 
BMP7 and CHIR99021 for an additional 20 days to generate IM cells highly expressing 
OSR1, a specific marker of IM. The authors documented that these cells also expressed 
several markers specific to cell types of both embryonic (ND, UB, MM and metanephric 
stromal cells) and mature kidney. However, when hiPSCs-derived IM cells were 
cocultured with E11.5 mouse metanephric cells to generate 3D chimeric aggregates, they 
formed polarised proximal tubular-like structures with low efficiency and exhibited scarce 
differentiation capacity into UB cells, indicating a limited developmental potential.  
In view of these limitations, the same group improved the efficiency of the protocol by 
skipping the stage of mesoderm induction and stimulating the hiPSCs exclusively with 
small molecules - CHIR99021 and retinoic acid receptor agonists - for 5 days. This 
modification significantly increased the capacity of hESC/hiPSC-derived IM cells to form 
proximal tubular-like structures within chimeric aggregates (Araoka et al., 2014).  
Following a similar line of research, Lam et al. reported a robust protocol for hPSC 
differentiation into IM cells that spontaneously formed tubule-like structures (Lam et al., 
2014). Initial treatment of hPSCs with CHIR99021 for 1-2 days induced mesendoderm 
differentiation. Cells were then treated with a combination of FGF2 and retinoic acid for 3 
days to generate PAX2- and LHX1-positive IM cells with high efficiency. When the 
authors withdrew growth factors from culture media, differentiated cells proliferated and 
formed polarised tubular epithelial structures positive for the proximal tubule markers LTL 
and N-cadherin, and endowed with primary cilia on the apical surface. Nevertheless, when 
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recombined with E12.5 mouse kidney cells to form chimeric kidney explants, these cells 
partially contributed to laminin-bounded tubular structures, indicating a low integration 
potential into developing kidney tissue. In another set of experiments, PAX2- and LHX1-
positive IM cells were stimulated with FGF9 - a growth factor known to induce and 
maintain nephron progenitors in vitro (Barak et al., 2012) - and Activin A to differentiate 
into CM cells expressing SIX2, SALL1 and WT1. In chimeric kidney explants, these hPSC-
derived CM cells were found in organising clusters of LTL-positive cells (Lam et al., 
2014). 
Xia et al. established a rapid and efficient two-step protocol for hESCs and hiPSCs 
directed differentiation into UB progenitor-like cells (Xia et al., 2013). In the first step, 
hPSCs were committed to mesodermal fate by exposure to BMP4 and FGF2 for 2 days. In 
the second step, combined treatment with BMP2, Activin A and retinoic acid drove cells to 
acquire a late IM/UB-like phenotype. After 4 days of differentiation, cells expressed high 
levels of IM and ND/ureteric epithelium markers (OSR1, LHX1, PAX2 and GATA3), and 
UB-specific markers (HOXB7, RET and GFRA1), rather than MM markers. To investigate 
the hPSC-derived UB-like progenitor cells for their propensity to contribute to complex 3D 
renal structures, the authors cocultured them with E11.5 mouse kidney cells to form 3D 
chimeric organoids. Under these culture conditions, the human cells exclusively integrated 
into the murine developing UB structures, indicating efficient in vitro UB-lineage 
commitment and ex vivo maturation capacity in response to renal developmental cues from 
mouse embryonic kidney cells (Xia et al., 2013, 2014). Moreover, the chimeric UB 
epithelia became polarised along the apical-basal axis and induced MM condensation and 
nephrogenesis, as occurs in vivo. In agreement with the absence of MM marker expression, 
differentiated human cells did not integrate at all in the MM derivatives.    
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In the past few years, significant advances towards the generation of multilineage and/or 
functional kidney organoids have been made by exposing hPSCs to chemically defined 
culture conditions that more accurately mimic early kidney developmental cues in vitro.  
Working on this approach, Takasato et al. established a protocol for the stepwise 
simultaneous differentiation of hESC monolayers towards UB and MM cells under 
chemically defined culture conditions (Takasato et al., 2014). In the first step, hESCs were 
induced to posterior primitive streak by exposure to either BMP4 and Activin A or 
CHIR99021 alone. Next, these cells were differentiated into IM cells using FGF9 and 
heparin. Finally, IM cells were stimulated with a combination of FGF9, heparin, BMP7 
and retinoic acid to derive MM cells. Otherwise, CHIR99021-treated cell lines were 
deprived of any growth factors for 12 days to generate a mixed population of both UB and 
MM progenitor cells. When reaggregated following monolayers’ dissociation into single 
cell suspensions, UB and MM progenitor cells self-organised to form human 3D kidney 
tubular structures in the absence of any other supporting cell type or tissue. Furthermore, 
upon coculture with E12.5 murine kidney cells to form chimeric aggregates, the hESC-
derived kidney progenitor cells integrated into all cellular compartments and epithelia of 
the developing kidney tissue (Takasato et al., 2014).  
In parallel, Taguchi et al. optimised a differentiation protocol to derive MM cells 
expressing WT1, PAX2, SALL1 and SIX2 from both mouse ESCs and hiPSCs, by first 
defining MM developmental origins through in vivo lineage-tracing studies, and then by 
accurately mimicking them in vitro (Taguchi et al., 2014). The authors demonstrated that 
MM progenitor cells derive from the posterior nascent mesoderm expressing Brachyury - a 
primitive streak and posterior nascent mesoderm marker (Herrmann et al., 1990) - and they 
established a combination of factors for inducing posterior mesoderm and its subsequent 
differentiation into MM. To induce posterior mesoderm differentiation, embryoid bodies 
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(EBs) from PSCs were initially treated with Activin A alone, and then with the 
combination of BMP4 and CHIR99021. Subsequently, IM identity was achieved by 
combined treatment with Activin A, BMP4, CHIR99021 and retinoic acid. Finally, 
differentiation into MM cells was accomplished using CHIR99021 and FGF9. Coculture of 
MM cell-aggregates with mouse embryonic dorsal spinal cords resulted in MM cell 
maturation and reconstitution of contiguous 3D glomerular structures, and proximal and 
distal tubules. When co-transplanted with dorsal spinal cords below the kidney capsule of 
immunodeficient animals, the EB-derived MM cell aggregates underwent massive 
tubulogenesis and developed vascularised glomeruli containing erythrocytes, indicating the 
graft’s connection to host circulation (Taguchi et al., 2014). Although vascularised 
glomeruli are required for blood filtration, neither urine production nor any other kidney 
functions were shown.    
Later, the same group, generated hiPSC lines expressing green fluorescent protein (GFP) in 
the NPHS1 locus - which encodes the podocyte slit diaphragm protein nephrin - and, 
differentiating these cells according to previous protocol, induced formation of 3D GFP-
glomerular structures containing nephrin-positive podocytes with primary processes and 
immature slit diaphragm-like structures (Sharmin et al., 2016). Next, the authors 
transplanted the sorted 3D GFP-positive glomerular structures beneath the host kidney 
capsule. Here, the glomerular structures further matured, were vascularised by host 
endothelial cells, and developed podocytes with foot processes wrapping the fenestrated 
endothelium (Sharmin et al., 2016). Importantly, the hiPSC-derived podocytes displayed 
both gene expression pattern and structural features typical of in vivo podocytes. 
By recapitulating metanephric kidney development in vitro, Morizane et al. have recently 
published a differentiation protocol to obtain MM cells expressing SIX2, SALL1 and WT1 
from hPSCs. Moreover, the authors demonstrated that the hPSC-derived nephron 
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progenitor cells could spontaneously assemble into human kidney organoids in both 2D 
and 3D culture conditions (Morizane et al., 2015). Specifically, to stimulate consecutive 
differentiation into primitive streak and posterior IM, hiPSCs were cultured in the presence 
of CHIR99021 and Noggin - a BMP4 signaling antagonist - for 4 days, and then with 
Activin A alone for additional 3 days, respectively. To establish MM identity and induce 
cell self-organisation, cells were stimulated with FGF9 for another 7 days, with transient 2-
day treatment with CHIR99021 starting on day 9. Finally, cell culture in the absence of 
growth factors for additional 14 days led to the spontaneous formation of hPSC-derived 
‘nephron organoids’ containing appropriately segmented nephrons, but completely lacking 
of UB derivatives. Remarkably, by exposing organoids to commonly used antibiotics and 
anticancer drugs, the authors demonstrated that they could be used as a tool to investigate 
mechanisms of proximal and/or distal tubular toxicity in vitro (Morizane et al., 2015).  
Almost simultaneously, the same group showed that hPSC-derived kidney cells could self-
organise to generate tubular organoids, recapitulate kidney epithelial transport, and, 
following genome editing, could model human kidney disease (Freedman et al., 2015). The 
authors developed a 3D culture system for sequential generation of hPSC-derived epiblast 
spheroids and kidney tubular organoids. In this system, hPSCs were first embedded in 
Matrigel to spontaneously form spheroids consisting of a polarised epithelium surrounding 
a hollow lumen in 3 days. Subsequent exposure to CHIR99021 for 1.5 days followed by 
incubation in B27-supplemented media for 11.5 days induced epiblast spheroid 
differentiation into kidney tubular organoids in which tubules positive for podocyte, 
vascular, proximal and distal tubular markers developed, and exhibited transport 
characteristics typical of proximal tubules. Interestingly, when biallelic truncating 
mutations in PKD1 (polycystin-1) or PKD2 (polycystin-2) genes were introduced in hPSCs 
through the CRISPR/Cas9 genome editing technology, kidney tubular organoids formed 
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large LTL-positive cyst-like structures alongside proximal tubular structures. Although this 
represents the first report of 3D kidney organoids capable of modelling human kidney 
disease in vitro, cysts formation was detected in only 6% of the self-forming organoids.   
In parallel, Takasato et al. modified their previous protocol (Takasato et al., 2014) in order 
to induce hiPSC differentiation and self-organisation into 3D kidney organoids composed 
of UB epithelia and MM-derived segmented nephrons, endothelial cells and renal stroma 
(Takasato et al., 2015). The in vitro self-forming organoids resulted transcriptionally 
similar to first trimester human foetal kidneys. Moreover, from the bottom to the top 
regions, organoids showed multiple individual collecting ducts linked to the distal and 
proximal tubules, and glomeruli containing podocytes with primary and secondary foot 
processes. The proximal tubular cells were capable of absorbing labelled macromolecules 
and underwent specific apoptosis in response to cisplatin, indicating tubular functional 
maturation (Takasato et al., 2015).  
Very recently, by recapitulating kidney developmental stages in vitro, our group set up a 
robust three-step protocol for hiPSC differentiation into functional podocytes (Ciampi et 
al., 2016). The hiPSCs were first specified into IM, then committed to nephron progenitor 
cells and, finally, differentiated into mature podocytes with typically low proliferation rate. 
The hiPSC-derived podocytes resulted able to endocytose and accumulate albumin in the 
perinuclear regions, and displayed cytoskeletal reorganisation when treated with 
Angiotensin II, a known inducer of podocyte damage. Moreover, when human podocytes 
from differentiation day 13 were reaggregated with E12.5 mouse kidney cells to form 
chimeric organoids, they incorporated into WT1-positive developing structures, where they 
also started to express WT1 (Ciampi et al., 2016).   
The technologies described in the paragraphs above strongly fostered the creation of 
kidney epithelial tubular structures that, in part, resemble their counterparts in vivo, and 
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hPSC-derived kidney organoids displaying considerable structural complexity and 
functional maturation. 
However, they cannot accurately replicate normal kidney tissue patterning, due to the 
organ’s complex architecture and the finely orchestrated interactions occurring between 
ECM and several cell lineages during organogenesis. Indeed, as kidney tubule and 
organoid formation solely relied on cell-driven self-assembly - reason why cells were not 
geometrically directed to acquire appropriate spatial configuration - engineered tubules 
were heterogeneous in size and shape and far from being anatomically realistic, whereas 
kidney organoids displayed serious developmental anomalies and structural malformations. 
First and foremost, within the organoids, the UB was either totally missing or developed as 
a multitude of small individual ducts (Taguchi et al., 2014; Freedman et al., 2015; 
Morizane et al., 2015; Takasato et al., 2015; Xia et al., 2013; Xinaris et al., 2016) instead 
of a unique collecting duct system of tubules that could drain urine away to a single exit if 
the tissue were vascularised. These anatomical deficiencies prevented development and 
maturation of kidney tissue arranged organotypically around one single and branched 
UB/collecting duct system, as instead occur during normal kidney organogenesis. Another 
issue is the short viability (3-4 weeks) of the organoids in vivo, as they soon after begin to 
degenerate.  
Additional technical insufficiencies of the existing tubule engineering systems are the 
requirement for extensive cell culturing -  from several days to weeks (Montesano et al., 
1991a; Sakurai et al., 1997) - as well as the need for other cell types (Montesano et al., 
1991a), tissues (Steer et al., 2002; Santos et al., 1994) or conditioned media (Montesano et 
al., 1991b; Sakurai et al., 1997).  
Overall, the constrictions described above hinder the reliability, reproducibility, cost-
effectiveness, and applicability of all these technologies. Moreover, systems for 
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engineering pure kidney units developed so far have not been adopted when using human 
cell sources, thus limiting investigations concerning human kidney developmental and 
pathophysiological mechanisms. 
 
To summarise, the generation of renal tubular structures and hPSC-derived kidney 
organoids has created considerable advances in the field, providing opportunities for 
disease modelling and toxicology studies. However, the usefulness of these tissues is 
limited because of serious technical weak points and anatomical deficiencies related to the 
UB development, namely the lack of collecting ducts or their random formation as multiple 
disconnected units within the organoids.  
Although Xia et al. attempted to derive collecting duct cells from hPSCs, they obtained 
UB-like cells that did not demonstrate significant UB tissue formation and maturation 
capacities (Xia et al., 2013).  
Therefore, developing 3D tissue engineering systems that could direct the generation and 
growth of unique and complex UB/collecting duct units from hiPSCs may be extremely 
helpful for creating more realistic human kidney tissue that bona fide resembles normal 
kidney anatomy and physiology, and that can be used for disease modelling and drug 
testing/discovery studies. Moreover, this kind of engineering system would allow the 
generation of patient-specific kidney tissue - an unresolved challenge in the field - useful 
for studying kidney diseases caused by abnormal developmental processes that cannot be 
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1.5 Specific Aims 
1) To develop and optimise a 3D culture method to engineer functional epithelial kidney 
tubules using micro-patterned scaffolds and a distal tubule/collecting duct renal cell 
line. 
 
2) To use this method as a tool to:  
- Model kidney disease and perform drug testing/discovery studies; 
- Engineer human epithelial tubules using hiPSC-derived UB progenitor-like cells; 
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2.1 PDMS scaffold fabrication  
Polydimethylsiloxane (PDMS) scaffolds (Sylgard 184 Silicone elastomer kit, Dow 
Corning, Midland, MI) were fabricated by NanoMed Labs (University of Genova, Italy) 
using a 3-step prototyping approach: scaffold design, 3D printing and replica moulding. 
First, by using Computer Aided Design (CAD) software (Autodesk 123D® Design ©2014 
Autodesk Inc.), scaffolds were designed with different geometries: (i) three scaffolds with 
width and depth of 1 mm: a linear one with a straight cavity, a bifurcated one with terminal 
80° branching and an asymmetrical one with two 30° lateral branches extending from the 
central trunk; (ii) two more complex ramified and tree-like scaffolds, the latter containing a 
fractal-like pattern, both 0.7 mm in depth, and ranging in width from 0.7 to 0.5 mm, 
respectively; (iii) a multichannel scaffold containing 11 linear microchannels, which were 
0.4 mm in depth x 0.4 mm in width x 9 mm in length, within a miniaturised culture 
chamber (1 mm in depth). 
3D printing technology (Professional Desktop Pico Plus39 stereolithographic 3D printer, 
Asiga Global Helpdesk) was applied to build plastic masters (Asiga PlasWhite 
photopolymer resin). The printer uses an upside-down system with nominal XY pixel 
resolution down to 39 m and servo resolution of 250 nm. The masters were printed at 0.5 
seconds of exposure time, with a printing speed of 0.33 cm/hour and 10 m vertical step 
size. After printing, masters were cleaned by rinsing with isopropyl alcohol for 5 minutes, 
washed in distilled water, dried and exposed to UV light (365 nm) (Bio-Link-BLX-365 
nm, 80 W, Vilber Lourmat) for 40 minutes to complete curing. To facilitate the de-
moulding of the polymeric replicas, masters were functionalised with an oxygen plasma 
treatment (Tucano plasma reactor Gambetti Kenologia) and with the deposition, from 
vapour phase, of an anti-sticking layer of Trichloro (1H,1H,2H,2H-perfluorooctyl) silane 
(FOTS, 448931-10G, Sigma-Aldrich, Saint Louis, Missouri, USA). Subsequent REplica 
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Moulding (REM) steps provide several polymeric replicas starting from a single master as 
previously described (Angeli et al., 2015). Briefly, the PDMS base and the curing mixture 
(10:1 w/w) were cast into 3D printed masters, degassed using a vacuum desiccator for 20 
minutes, cured at 60 °C in oven for 2 hours, and then peeled off the master mould. Finally, 
the bottom side of the cavities was closed up with a 20 µm-thick PDMS layer. After 
assembling, cavities were open-topped and completely made of PDMS. In order to enable 
high-resolution imaging, the thickness of the PDMS scaffolds was maintained between 0.7 
and 1 mm. Scaffold hydrophobicity was preserved to avoid cell attachment. PDMS 
Scaffolds were re-used after standard sterilisation procedures. 
 
2.2 Madin-Darby canine kidney (MDCK) cell culture  
The MDCK type II cell line (MDCK II; 00062107; Lot Number 06D026; Origin: Canine 
Cocker Spaniel Kidney; European Collection of Authenticated Cell Cultures, ECACC, 
Salisbury, UK) was maintained in Minimum Essential Medium Eagle (MEM) (M5650; 
Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (FBS) (10270; Invitrogen 
Corporation, Carlsbad, CA, USA), 1% L-glutamine (25030024; Invitrogen), 1% penicillin 
and streptomycin (Pen-Strep) (15140122; Invitrogen). Cells were cultured as monolayers 
in tissue culture-treated T75 (75 cm2) flasks (353136; Corning Falcon®, Corning, NY, 
USA) under standard conditions (37°C incubator, humidified atmosphere of 5% CO2). For 
passaging, 70-80% confluent MDCK cells were washed once with sterile filtered pre-
warmed BioWhittaker® 1x phosphate buffered saline (PBS) pH 7.2 without Ca2+ and Mg2+ 
(BE17-516F; Lonza, Verviers, Belgium), and then were treated with 3 ml of pre-warmed 
0.25% Trypsin-Ethylenediaminetetraacetic Acid (EDTA) (25200056; Invitrogen) for 4 
minutes at 37°C. Detached cells were gently pipetted 2-3 times to ensure complete 
dissociation of any remaining clumps and dislodgement of any cells still attached to the 
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bottom of the flask. Next, cells were collected in a 50 ml conical tube containing the 
appropriate volume of culture medium, counted and seeded in T75 flasks at a density of 
1.6x104 cells/cm2 in 15 ml of fresh culture medium. Cells were maintained for 3 days 
without culture medium change until subsequent passaging.  
 
2.3 Human induced pluripotent stem cell (hiPSC) culture 
The hiPSC lines used in our experiments were derived from healthy donor somatic cells by 
different technologies and characterised as previously described (Imberti et al., 2015; 
Ciampi et al., 2016). Specifically, hiPSC clone IV was obtained from human dermal 
neonatal fibroblasts via STEMCCA lentivirus-mediated reprogramming (Imberti et al., 
2015), whereas hiPSC#16 cells were derived from peripheral blood mononuclear cells 
(PBMCs) through non-integrative Sendai virus-mediated reprogramming (Ciampi et al., 
2016). For feeder-free culture conditions, cells were maintained in mTeSR1 medium 
enriched with mTeSR1 5X Supplement (05850; Complete Kit; StemCell Technologies, 
Vancouver, Canada), and cultured as monolayers on Matrigel hESC-qualified Matrix 
(354277; Corning)-coated 100x20 mm dishes (353003; Corning) under standard 
conditions. Matrigel hESC-qualified Matrix was used following the manufacturer’s 
instructions. Briefly, aliquots were prepared according to the dilution factor indicated on 
the Certificate of Analysis and frozen at -80°C. One aliquot was thawed on ice and added 
to 25 ml of ice-cold DMEM/F12+GlutaMAX (31331028; Invitrogen) to coat the dishes (5 
ml/dish), which were then incubated at room temperature for at least 1 hour before use. 
The remaining coating liquid was aspirated from the dish just before hiPSC seeding on top 
of the thin gel layer.  
When 80% confluent, hiPSCs were abundantly washed with PBS and then treated with 3 
ml Accutase (a1110501; Invitrogen) for 4 minutes at 37°C for passaging. Detached cells 
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were gently pipetted 2-3 times to ensure complete dissociation of any remaining clumps 
and dislodgement of any cells still attached to the bottom of the dish. Next, cells were 
collected in 50 ml conical tube containing culture medium, counted, and seeded onto 
Matrigel hESC-qualified Matrix-coated dishes at a density of 4.5x104 cells/cm2 in the 
appropriate volume of fresh mTeSR1 complete medium supplemented with 10 M Y-
27632 dihydrochloride [Rho-associated protein (ROCK) inhibitor; 07172; Sigma-Aldrich] 
for the first 24 hours to avoid/reduce cell death for apoptosis. The hiPSCs were maintained 
in 10 ml of mTeSR1 complete medium for 3-5 days, with daily medium change, until 
subsequent passaging.  
 
2.4 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs (lymphocytes, monocytes, and thrombocytes) were isolated under sterile 
conditions from 40 ml of whole blood taken from a patient carrying a heterozygous 
mutation in the PAX2 gene. Patient’s whole blood was collected in sterile 50 ml conical 
tube and 10 U/ml heparin (Pharmatex Italia, Milan, Italy) were added to prevent blood 
coagulation. The blood was diluted 1:1 with saline solution (Pharmatex Italia) and 20 ml of 
diluted sample were delicately layered over 15 ml of Ficoll-PaqueTM (17-1440-02; GE 
Healthcare Life Sciences, Little Chalfont, UK) in a total of 4 sterile 50 ml conical tubes, 
which were centrifuged 800xg for 20 minutes at room temperature without brake. Next, 
tubes were recovered from the centrifuge taking care of not disturbing the layering. The 
layer containing PBMCs, which was positioned at the interphase, was gently aspirated 
carefully avoiding Ficoll-PaqueTM aspiration, and was transferred to new 50 ml conical 
tube. At this point, PBS was added to reach a final volume of 50 ml, and the suspension 
was centrifuged at 400xg for 8 minutes at room temperature. Then, supernatant was 
discarded and cell pellet was washed again using PBS. After discarding the supernatant, 2 
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ml of RPMI medium (11875093; Thermo Fisher Scientific, MA, USA) supplemented with 
20% human serum-AB were added and PBMC pellet was resuspended to obtain a uniform 
suspension of single cells. After cell counting, aliquots of 5-10x106 PBMCs were gently 
dropped into cryovials containing 1-1.5 ml of freezing medium [RPMI medium 
supplemented with 20% human serum-AB and 10% dimethyl-sulphoxide (DMSO) 
(D2650; Sigma-Aldrich)]. After the cells were exposed to freezing medium containing 
DMSO, they were frozen within 2 minutes by placing cryovials in a cryofreezing container 
and transferring it to -80°C overnight. This manoeuvre allows freezing the cells at 1°C per 
minute. After overnight storage, cryovials were transferred into a liquid nitrogen tank 
vapour phase for long-term storage. 
 
2.5 Generation of patient-derived iPSCs 
The patient involved in this study is affected by an autosomal dominant form of Focal 
Segmental Glomerulosclerosis (FSGS) linked to a disease-segregating missense 
heterozygous genetic mutation in PAX2 gene (c.G565A, p.G189R) (Barua et al., 2014). 
FSGS patient-derived iPSCs were generated from PBMCs (the written informed consent 
was obtained from the patient in accordance with the Declaration of Helsinki guidelines) 
through Sendai virus-mediated reprogramming by using CytoTune-iPS 2.0 Sendai 
Reprogramming kit (A16517; Thermo Fisher Scientific) according to the manufacturer’s 
instructions as follows:  
 
2.5.1 PBMCs seeding. Four days before infection, cryopreserved PBMCs were thawed in 
37°C water bath,  gently transferred into 15 ml conical tube containing 10 ml of 
pre-warmed complete PBMC medium [StemPro®-34 medium (10639-011) 
supplemented with 2 mM L-Glutamine (25030), 100 ng/ml human recombinant 
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SCF (c-kit Ligand) (PHC2111), 100 ng/ml human recombinant FLT-3 Ligand 
(PHC9414), 20 ng/ml human recombinant IL-3 (PHC0034), and 20 ng/ml human 
recombinant IL-6 (PHC0065). All PBMC medium components were purchased 
from Thermo Fisher Scientific] and centrifuged at 200xg for 10 minutes at room 
temperature. An aliquot of cells was taken for cell counting before centrifugation. 
After centrifugation, supernatant was discarded, and pellet was resuspended in 
complete PBMC medium to 5x105 cells/ml. Next, 1 ml per well was dropped in 24-
well plates (3527; Corning), and PBMCs were cultured as suspension of not-
proliferating cells under standard conditions for the next 3 days, with daily 500 l 
(half) medium change without disturbing the cells.  
 
2.5.2 PBMC infection. The day of infection (day 0), PBMCs were harvested, and 
brought to 3x105 cells/ml into sterile, round-bottom and screw capped centrifuge 
tubes (352054; Corning). At this point, PBMCs were infected by adding 5 
multiplicity of infection (MOI) of hKLF4-OCT4-SOX2 (hKOS) Sendai virus 
vector, 5 MOI of hc-Myc Sendai virus vector, and 3 MOI of hKLF4 Sendai virus 
vector in a total volume of 1 ml. Both Sendai reprogramming tubes’ thawing and 
virus volume calculation were performed following the manufacturer’s instructions. 
To increase transduction and reprogramming efficiencies, capped tubes were 
centrifuged at 2,250 rpm for 30 minutes at room temperature using the SL-16 
centrifuge (Thermo Fisher Scientific). After centrifugation, PBMC pellets were 
resuspended in the same virus-containing medium, and 1 ml of fresh PBMC 
complete medium was added to each tube. At this point, PBMCs were seeded in 
12-well plates (3513; Corning) and incubated overnight under standard conditions. 
The next day (day 1 post-infection), both cells and medium were harvested from 
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the wells and transferred into centrifuge conical tube. Each well was rinsed with 1 
ml of PBMC complete medium to ensure harvesting most of the cells, and volumes 
were added to the centrifuge tube. PBMC suspension was centrifuged at 200xg for 
10 minutes, supernatant was discarded, and cells were resuspended in 500 l of 
PBMC complete medium per well of 24-well plate. Cells were seeded and cultured 
under standard conditions for the next 2 days (day 2 and 3 post-infection).  
 
2.5.3 Cell seeding on mouse embryonic fibroblasts (MEFs). MEFs were isolated from 
CD1 mouse (Charles River Italia S.p.A., Calco, Lecco, Italy) embryonic day (E) 
13.5 embryos, and used as feeder layers for hiPSC generation. MEFs were cultured 
in T75 flasks as monolayers under standard conditions in Dulbecco’s Modified 
Eagle Medium (DMEM) (11960044; Invitrogen) supplemented with 10% FBS 
(16000; Invitrogen), 0.1 mM non-essential amino acids (11140050; Invitrogen) and 
1% Pen-Strep. When 95% confluent, MEFs were mitotically inactivated by treating 
them with 0.01 mg/ml mitomycin-C (M4287; Sigma-Aldrich) for 2 hours, and then 
seeded on 6-well plates (353046; Corning) at a density of 8x104 cells/cm2. At day 3 
post-infection, 1-5x104 live PBMCs per well were seeded on mitotically inactivated 
MEFs in a total volume of 2 ml StemPro®-34 medium without cytokines, and 
cultured under standard conditions for other 3 days (day 4-6 post-infection). From 
day 4 to day 6, 1 ml (half) of StemPro®-34 medium without cytokines was 
replaced every other day with the same amount of fresh medium, taking care of not 
disturbing cells.  
 
2.5.4 Transitioning-PBMC exposure to hiPSC-medium. On day 7 post-infection, 1 ml 
(half) of StemPro®-34 medium without cytokines was replaced with the same 
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amount of hiPSC-medium [DMEM/F12+GlutaMAX supplemented with 20% 
knock-out serum (10828028; Invitrogen), 0.1 mM non-essential amino acids, 0.1 
mM 2-mercaptoethanol (M6250; Sigma-Aldrich), 10 ng/ml human fibroblast 
growth factor 2 (FGF2) (100-18B; PeproTech, NJ, USA), and 1% Pen-Strep]. The 
next day (day 8 post-infection), culture medium was completely replaced with 2 ml 
of hiPSC-medium, which was changed every day thereafter with the same amount 
of fresh medium, until the appearance of the first cell colonies (about day 10-12 
post-infection), indicative of reprogrammed cells.  
 
2.5.5 Picking of patient-derived iPSC colonies and cell expansion. When 
reprogrammed cell colonies grew to an appropriate size (̴ 500 m in diameter; day 
21 post-infection), they were manually picked under an inverted microscope placed 
in a sterile cell culture hood. The colonies to be picked were cut in 4 similarly-sized 
pieces using a sterile 25-gauge 11/2-inch needle (insulin-needle) directly in the cell 
culture wells. Cut pieces were gently aspirated with a 200 l micropipette (Gilson, 
Inc., Middleton, USA), transferred into sterile Eppendorf® Safe-
Lock microcentrifuge tubes (T9661; Sigma-Aldrich), containing 500 l of hiPSC-
medium and fragmented into smaller clumps by gently pipetting. At this point, 
clumps were aspirated and seeded onto newly prepared MEF feeder layers in wells 
of 6-well plates in 2 ml of hiPSC-medium - supplemented with 10 M ROCK 
inhibitor for the first 24 hours - and cultured under standard conditions. Clumps 
were allowed to attach and grow as large hiPSC colonies, and culture medium was 
changed daily. In order to be expanded, 70-80% confluent hiPSC colonies were 
mechanically split (manual picking) for 4 passages, and seeded on freshly prepared 
MEF feeder layers.  
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2.5.6 Patient-derived iPSCs adaptation to feeder-free culture conditions. Patient-
derived iPSCs grown and expanded on MEF feeder layers were cut and manually 
picked as described in the paragraph 2.5.5. Cut pieces were transferred into sterile 
Eppendorf® Safe-Lock microcentrifuge tubes containing 500 l of mTeSR1 
complete medium and fragmented into smaller clumps by firmly pipetting. At this 
point, clumps were aspirated and seeded onto Matrigel hESC-qualified Matrix-
coated wells of 6-well plates in 2ml of mTeSR1 complete medium - supplemented 
with 10 m ROCK inhibitor for the first 24 hours - and cultured in feeder-free 
conditions as described in the paragraph 2.3. Patient-derived hiPSC#1 clone was 
selected for characterisation and additional experiments (see the paragraph 2.6 
below). 
 
2.6 Characterisation of patient-derived iPSCs  
To characterise patient-derived iPSCs (hiPSC#1 clone) we: (i) performed 
immunofluorescence and quantitative real-time PCR (qRT-PCR) analyses to evaluate 
pluripotency marker expression, (ii) tested cell capacity to form embryoid bodies (EBs) as 
a stringent assay to screen for pluripotency, (iii) investigated stochastic differentiation of 
the cells forming the EBs into all three somatic germ layers, and (iv) carried out karyotype 
analysis.  
 
2.6.1 Immunofluorescence staining. For immunofluorescence analysis, patient-derived 
iPSCs were washed three times with 2 ml of PBS and fixed in PBS containing 4% 
paraformaldehyde (PFA) (157-8; Electron Microscopy Sciences, Hatfield, PA, 
USA) for 15 minutes at room temperature. Next, cells were permeabilised with 
0.3% Triton X-100 (93418; Sigma-Aldrich) prepared in PBS for 10 minutes at 
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room temperature, blocked with PBS containing 5% bovine serum albumin (BSA) 
(A2153; Sigma-Aldrich) for 1 hour at room temperature, and incubated with the 
primary antibodies diluted in PBS containing 2% BSA (Sigma-Aldrich). Primary 
antibodies: rabbit anti-NANOG (sc-33759; Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA; 1:100), mouse anti-OCT4 (sc-5279; Santa Cruz Biotechnology; 
1:100), mouse anti-TRA 1-60 (MAB4360; Merck-Millipore, NJ, USA; 1:200), 
mouse anti-TRA 1-81 (MAB4381; Merck-Millipore, 1:200), rat anti-SSEA3 (sc-
21703; Santa Cruz Biotechnology; 1:100) and mouse anti-SSEA4 (sc-21704; Santa 
Cruz Biotechnology; 1:100) over night at 4°C.  
The next day, samples were abundantly washed with PBS and incubated for 1 hour 
at room temperature in the dark with the appropriate secondary antibodies diluted 
in PBS containing 2% BSA (Sigma-Aldrich). Secondary antibodies: Donkey anti-
Rabbit IgG Alexa Fluor® 546-conjugated (A10040; 1:300), Goat anti-Rat IgM 
Alexa Fluor® 488-conjugated (A21212; 1:300), Donkey anti-Mouse IgG Alexa 
Fluor® 546-conjugated (A10036; 1:300) and Goat anti-Mouse IgM Alexa Fluor® 
488-conjugated (A21042; 1:300). All secondary antibodies were purchased from 
Thermo Fisher Scientific. After incubation with secondary antibodies, cells were 
washed twice with PBS for 5 minutes, and then nuclear staining was performed by 
incubating cells with 1 mg/ml 4’,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) (D9542; Sigma-Aldrich) for 10 minutes in the dark. DAPI was prepared 
and stored according to the manufacturer’s instructions. Images were taken with the 
CF40 Axiovert fluorescence microscope (Carl Zeiss, Oberkochen, Germany) and 
are representative of three independent experiments.  
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2.6.2 Embryoid body (EB) formation and patient-derived hiPSC differentiation into the 
three germ layers. For EB formation, sub-confluent patient-derived iPSCs were 
harvested as described in paragraph 2.3, and counted. Before cell seeding, 
AggreWellTM800 plates (27965; Stem Cell Technologies), which are endowed with 
microwells of 800 m in diameter, were centrifuged at 2,000xg for 5 minutes in a 
swinging bucket rotor with plate-holders in order to remove any air bubbles from 
the microwells. To obtain 3,000-4,000 cell-sized EBs, the harvested hiPSCs were 
first resuspended in order to have 1x106 hiPSCs/well in 1.5 ml/well of 
AggreWellTM medium (EB medium; 05893; Stem Cell Technologies) 
supplemented with 10 M ROCK inhibitor, and then were seeded. Soon after 
seeding, cell suspension in each well was gently pipetted several times to 
homogeneously distribute the cells. Next, plate was centrifuged at 100xg for 3 
minutes at room temperature for capturing cells in the microwells and was finally 
incubated under standard conditions. EBs formed within 2 days of culture. At this 
point, EBs were displaced and harvested by firmly pipetting 2-3 times the EB 
medium in each well. Then, EBs were transferred into 6-well ultra-low-adherence 
plates (27145; Corning) (̴ 800 EBs/well) in a total volume of 5 ml/well of EB 
medium, and were cultured in suspension under standard conditions, changing EB 
medium every 2 days. After 8 days as floating cultures, EBs were transferred onto 
0.1% gelatine (G2500; Sigma-Aldrich)-coated plates [6-well plate coating was 
made by adding 2 ml/well of 0.1% sterile gelatine solution prepared in PBS 
(Lonza) and incubating plates at 37°C for 30 minutes] and cultured for another 8 
days, by changing EB medium every 2 days. Under these culture conditions, EBs 
gradually adhered to the gelatine-coated well bottom and grew as monolayered 
cells. On culture day 16, cells were fixed in PBS containing 4% PFA, and 
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processed for immunostaining as described in paragraph 2.6.1. In particular, 
differentiation into the three germ layers was evaluated by immunostaining the EB-
derived cells for Alexa Fluor® 488-conjugated mouse anti--Tubulin III (ectoderm 
marker; CBL412X; Merck-Millipore; 1:100), Cy3TM-conjugated mouse anti--
smooth muscle actin (SMA) (mesoderm marker; C6198; Sigma-Aldrich; 1:100) 
and rabbit anti-GATA4 (endoderm marker; sc-9053; Santa Cruz Biotechnology; 
1:50).  
 
2.6.3 Gene expression analysis. Gene expression level of pluripotency markers was 
analysed by performing qRT-PCR assays using predesigned Taqman probes 
(Thermo Fisher Scientific) specific to OCT4, NANOG and SOX2 genes (Table 1) as 
described in the paragraph 2.8 below. Gene expression levels were normalised to 
the housekeeping gene hypoxanthine phosphoribosyltransferase-1 (HPRT1). 
 
2.6.4 Karyotype analysis. When 60-70% confluent, patient-derived iPSCs were treated 
with 10 mg/ml Colcemid (10295892001; Roche, Basel, Switzerland) in mTeSR1 
medium for 2 hours and a half, in order to induce cell cycle synchronisation and 
increase the yield of metaphase chromosomes. After treatment, cells were harvested 
as described in the paragraph 2.3 and centrifuged at 1000xg for 6 minutes at room 
temperature. Soon after, pellets were delivered to the Genetic Medicine Laboratory 
of the Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo 
(Italy), where karyotype analysis was performed. Briefly, metaphase spreads 
(consisting of condensed metaphase chromosomes) were prepared onto microscope 
slides, and were processed for G-banding karyotype analysis. Twenty metaphases 
were analysed for the chromosomes’ size, shape and number. 
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2.7 Differentiation of hiPSCs toward ureteric bud (UB) progenitor-like cells  
The hiPSCs were induced to differentiate toward UB-like cells as previously described 
with minor modifications (Xia et al., 2013). When 70-80% confluent, hiPSCs cultured in 
6-well plates were abundantly washed with PBS and then treated with 2 ml of pre-warmed 
DMEM/F12+GlutaMAX (31331028; Invitrogen) containing 1 U/ml Dispase (1x Dispase; 
07913; StemCell Technologies) for 4 minutes at 37°C. After treatment, 1x Dispase was 
removed and cells were washed twice with 2 ml of DMEM/F12+GlutaMax. Next, 2 ml of 
DMEM/F12+GlutaMAX were added to each well and the hiPSC sub-confluent colonies 
were fragmented through gentle manual scraping with a 5 ml glass pipette into small 
clusters (each consisting of about 200-400 cells), which were then split onto Basement 
Membrane Growth-Factor-Reduced (GFR) Matrigel (356231; Corning)-coated 6-well 
plates at a ratio of 1:4. Basement Membrane GFR Matrigel was used following the 
manufacturer’s instructions. Briefly, 0.5 ml aliquots of Basement Membrane GFR Matrigel 
were prepared and frozen at -80°C. One aliquot was thawed on ice and added to 15 ml of 
cold DMEM/F12+GlutaMAX (31331028; Invitrogen) (1:30 dilution) to coat wells of 6-
well plates (1 ml/well), which were then incubated at room temperature for 1 hour prior to 
be used. Just before hiPSC seeding and culturing on top of the thin gel layer, the unbound 
coating liquid was aspirated from each well.  
After 24 hour-recovery in mTeSR1 complete medium supplemented with 10 M ROCK 
inhibitor, cell colonies were grown in 1.5 ml of chemically defined basal differentiation 
medium [DMEM/F12+GlutaMAX (Invitrogen), 17.5 mg/ml BSA fraction V (126579; 
Merck-Millipore), 17.5 µg/ml human insulin (I9278; Sigma-Aldrich), 275 g/ml human 
holo-transferrin (T0665; Sigma-Aldrich), 450 M 1-thioglycerol (M6145; Sigma-Aldrich), 
0.1 mM non-essential amino acids (Invitrogen), 1% Pen-Strep (Invitrogen)] supplemented 
with 50 ng/ml human fibroblast growth factor 2 (FGF2) (100-18B; PeproTech) and 30 
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ng/ml human bone morphogenetic protein 4 (BMP4) (120-05; PeproTech) for 2 days to 
induce mesoderm commitment. For the next 2 days, cells were exposed to the basal 
differentiation medium supplemented with 1 M all-trans retinoic acid (R2625; Sigma-
Aldrich), 10 ng/ml human Activin A (120-14E; PeproTech) and 100 ng/ml human bone 
morphogenetic protein 2 (BMP2) (H00000650-Q01; Abnova Corporation, Taiwan) for UB 
fate induction. 1.5 ml of appropriate differentiation medium was added daily. Activin A, 
all-trans retinoic acid, and all growth factors were reconstituted and stored in accordance 
with the manufacturer’s instructions.  
 
2.8 RNA isolation and gene expression analysis with quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR)  
Both undifferentiated (d0) and differentiated (d1-d4) hiPSCs were harvested with Accutase 
as described in the paragraph 2.3, and separately collected in 50 ml conical tubes. After 
cell counting, aliquots of 2-3x106 cells were transferred to 15 ml conical tubes, and 
centrifuged at 200xg for 5 minutes at room temperature. After centrifugation, supernatant 
was discarded, pellet was resuspended in 8 ml of PBS, and cell suspension was centrifuged 
again. Next, supernatant was carefully aspirated without disturbing the pellet, and dry 
pellets were stored at -80°C overnight or until RNA isolation procedure. Total cellular 
RNA was isolated with Trizol® Reagent (15596026; Invitrogen) according to the 
manufacturer’s instructions using the appropriate precautions to avoid RNase 
contamination. The total RNA yields and purity were determined by measuring the 
absorbance at 260 nm and 280 nm (A260/280 > 1.8), respectively, with NANODROP 1000 
UV/VIS spectrophotometer (Thermo Fisher Scientific) following dilution of the isolated 
RNA samples in RNase-free water on ice. To avoid DNA contamination, 10 g of total 
RNA were treated using the RQ1 RNase-free DNase kit (M6101; Promega Corporation, 
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Madison, WI, USA) [DNase treatment for 1 hour at 37°C in the presence of 1 U/l of 
SUPERaseInhTM RNase Inhibitor (AM2694; Invitrogen), followed by the addition of 
DNase STOP solution for 10 minutes at 65°C]. Purified RNA suspension volume was 
made up to 200 l with RNase-free water, and was precipitated by adding 20 l of 3M 
sodium acetate buffer pH 5.4 and 600 l of ice-cold 100% ethanol, overnight at -80°C. The 
next day, samples were centrifuged at 13,200 rpm for 30 minutes at 4°C in the Eppendorf® 
5415-R refrigerated microcentrifuge. After centrifugation, supernatant was discarded, 
pellets were washed by gently adding 500 l of ice-cold 75% ethanol, and were 
centrifuged at 13,200 rpm for 5 minutes at 4°C. Subsequently, supernatant was aspirated, 
pellets were resuspended with RNase free-water on ice, and the absorbance at 260 nm and 
280 nm was measured. At this point, 2.5 g of purified RNA were reverse-transcribed 
using SuperScript VILO cDNA synthesis kit (11754050; Invitrogen) adhering to the 
manufacturer’s instructions. No enzyme was added to reverse transcriptase-negative 
controls. Expression of pluripotency, early renal and UB-related markers was evaluated by 
TaqMan gene expression assay on ViiA 7 Real Time PCR system (Applied Biosystems, 
CA, USA) using predesigned TaqMan probes (Thermo Fisher Scientific) specific to 
NANOG, T, LHX1, PAX2, GATA3 and HOXB7 genes (Table 1) according to the supplier’s 
instructions. Gene expression levels were normalised to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The Ct technique was adopted 
to calculate cDNA content in each sample using cDNA expression of the pluripotent state 
(d0) as a calibrator. Three independent experiments for each hiPSC line were performed, 
and samples were analysed in triplicate. 
 
2.9 Kidney tubule engineering  
Sub-confluent MDCK type II cells and in vitro differentiated hiPSCs were harvested, as 
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described in the paragraphs 2.2 and 2.3, using pre-warmed 0.25% Trypsin–EDTA and 
Accutase, respectively. Once detached, cells were counted, collected in sterile Eppendorf® 
Safe-Lock microcentrifuge tubes containing the appropriate culture medium, and 
centrifuged at 300xg for 3 (hiPSCs) or 4 (MDCK cells) minutes in the CL17-R 
Microcentrifuge (75002455; Thermo Fisher Scientific). Subsequently, supernatant was 
completely discarded, pellets were resuspended in 2.4 mg/ml rat-tail collagen type I 
(354236; Corning) on ice taking care to avoid air bubble formation and obtain a 
homogeneous cell suspension, which was finally seeded into the PDMS scaffold cavities. 
Prior to cell seeding, PDMS macro- and microscaffolds were placed into sterile 60x15 mm 
(353004; Corning) and 35x10 mm (DTC035; Sterilin® Ltd, British Plastics Federation, 
Parkway, UK) tissue culture dishes, respectively. Rat-tail collagen type I was stored 
according to the manufacturer’s instructions and was gelled by bringing its pH to alkalinity 
following the gelation procedure described in the Certificate of Analysis provided by the 
producer. Optimal cell densities were set-up at 1.2x105 cells/l collagen and 2x105 cells/l 
collagen for macro- and microscaffolds, respectively. The total volume of seeded cell-
collagen mixture vary according to the size of the PDMS scaffold cavities. After collagen 
polymerisation, which for macroscaffolds occurs after 30 minutes at 37°C and for 
microscaffolds occurs after 2 minutes at room temperature, the appropriate culture medium 
(6 ml for macroscaffolds and 200-250 l for microscaffolds) was gently dropped to cover 
the scaffolds.  
Culture media: DMEM/F12+GlutaMAX supplemented with 1% FBS, 1% Pen-Strep and 
40 ng/ml hepatocyte growth factor (HGF) (100-39; PeproTech) for MDCK tubules; basal 
differentiation medium supplemented with 1% FBS, 40 ng/ml HGF and 100 ng/ml glial 
cell-derived neurotrophic factor (GDNF) (ab73450; Abcam, Cambridge, UK) for  hiPSC-
derived tubules.  
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Bright-field images of cultured tubules were obtained using Leica ZOOM 200 
stereomicroscope (Leica Microsystems, Wetzlar, Germany) and Primo Vert inverted 
microscope (Carl Zeiss). Both HGF and GDNF were reconstituted and stored following the 
manufacturer’s instructions. Tubules were cultured for up to 2 days in standard conditions 
without changing culture medium. 
 
2.10 Kidney tubule histological staining  
For cross-sectional histological analysis, 2-day cultured macrotubules were gently 
harvested with a 1000 l micropipette (Gilson), transferred into sterile 60x15 mm dish, 
washed with PBS for 10 minutes, and then fixed in PBS containing 4% PFA for 15 
minutes. After abundant washing with PBS, tubules were embedded in Optimal Cutting 
Temperature (OCT) compound (4583; Tissue-Tek, Sakura Finetek, Japan) and frozen at -
80°C. After freezing, 3-m serial tubule cryosections were cut using Leica CM1950 
cryostat (Leica), mounted on Polysine® slides (J2800AMNZ; Thermo Fisher Scientific) 
and immediately placed at -80°C. Subsequently, slides were submerged in Harris’s 
haematoxylin (05-M06004; Bio-optica) for 2 minutes, rapidly washed with distilled water, 
mounted with Ready-to-use Dako Faramount Aqueous Mounting Medium (S3025; DAKO 
Corporation, Carpinteria, CA, USA) and observed by light microscopy.  
Tubules 3D-cultured in Transwell inserts (see paragraphs 2.13 and 2.14 for details) were 
stained with haematoxylin and eosin as follows: firstly, they were washed with 2 ml PBS 
for 15 minutes, fixed in PBS containing 4% PFA for 45 minutes at room temperature, and 
washed again in PBS (at this point samples can be stored at 4°C in 3 ml PBS). Secondly, 
tubules were harvested from collagen (see the paragraph 2.13 for details on this 
manoeuvre), submerged in 3 ml of haematoxylin (05-M06012; Bio-Optica, Milan, Italy) 
diluted 1:6 in distilled water for 5 minutes, washed abundantly in distilled water and then 
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soaked in 3 ml of eosin (05-M10002; Bio-optica) diluted 1:9 in distilled water for 1 
minute. After washing, samples were placed on Polysine® slides, completely covered with 
Ready-to-use Dako Faramount Aqueous Mounting Medium, and observed by light 
microscopy.  
All digital images were acquired and analysed using AxioImager Z2 microscope and 
AxioVision 4.8 imaging software (Carl Zeiss), respectively. 
 
2.11 Kidney tubule immunofluorescence staining  
For immunofluorescence analysis, tubules were harvested from the scaffolds, fixed in PBS 
containing 4% PFA as described in the paragraph 2.10, washed in PBS for 10 minutes, and 
permeabilised in 100% ice-cold methanol (414814; Carlo Erba Reagents, Cornaredo, 
Milan, Italy) for 10 minutes. Next, samples were washed again and incubated with the 
following primary antibodies diluted in PBS: mouse anti-E-cadherin (610182; BD 
Biosciences, CA, USA; 1:100), rabbit anti-podocalyxin (NB110-41503; Novus 
Biologicals, Littleton, CO, USA; 1:80), rabbit anti-PKC- (C-20) (sc-216; Santa Cruz; 
1:100) and rabbit anti-cleaved caspase-3 (D175-5A1E; Cell Signaling Technology, MA, 
USA; 1:200) overnight at 4°C. After washing, tubules were incubated with the appropriate 
secondary antibodies diluted in PBS: CyTM3-conjugated AffiniPure Donkey Anti-Mouse 
IgG (715-165-151; 1:50), CyTM5-conjugated AffiniPure F(ab’)2 Fragment Donkey Anti-
Mouse IgG (715-176-151; 1:50), CyTM3-conjugated AffiniPure Donkey Anti-Rabbit IgG 
(711-165-152; 1:50) and Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Rabbit 
IgG (711-095-152; 1:50) overnight at 4°C in the dark. All secondary antibodies were 
purchased from Jackson ImmunoResearch Labs, PA, USA. After washing, samples were 
soaked in DAPI for 10 minutes to label cell nuclei, washed again, placed on 24x60 mm 
coverslips (Knittel Gleaser, Germany), and completely covered with Dako Fluorescence 
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Mounting Medium (S3023; DAKO Corporation).  
For the immunostaining of 3-m cross-sections, sample sections were permeabilised with 
PBS containing 0.3% Triton X-100 for 5 minutes, washed, blocked with 1% BSA solution 
in PBS for 30 minutes, washed again, and incubated overnight at 4°C with the indicated 
primary antibodies. After washing, sections were incubated with the appropriate secondary 
antibodies (Jackson ImmunoResearch Labs; 1:50) for 2 hours at room temperature in the 
dark, followed by washing and nuclear staining with DAPI for 10 minutes. Negative 
controls were obtained by omitting primary antibodies on adjacent sections on the same 
slide. Finally, slides were mounted with Dako Fluorescence Mounting Medium and 
examined. 
In some cases, samples were further labelled with wheat germ agglutinin-lectin (WGA-
lectin) (FL-1021; Vector Labs, Burlingame, CA, USA; 1:400) for 15 minutes or peanut 
agglutinin-lectin (PNA-lectin) (RL-1072; Vector Labs; 1:80) for 1 hour and 30 minutes, 
both diluted in PBS. Digital images were acquired using the LSM 510 Meta inverted 
confocal laser scanning microscope and LSM Image browser (Carl Zeiss). All images were 
analysed using the free open-source image processing ImageJ software (1.49v, National 
Institutes of Health).  
 
2.12 Functional studies  
After 2 days of culture in PDMS scaffolds, engineered tubules were harvested, transferred 
in transparent plastic tubes with screw cap, washed with 1 ml of PBS for 10 minutes, and 
then soaked in 500 l of PBS containing 25 mg/ml 10-KDa FITC-conjugated dextran 
(FD10S; Sigma-Aldrich) or 2 mM 6-Carboxyfluorescein (6CF) (C0662; Sigma-Aldrich) 
alone or in combination with 2 mM probenecid (P8761; Sigma-Aldrich) for 1 hour at 37°C 
in the dark. Subsequently, tubules were washed 4-5 times with ice-cold PBS, were fixed 
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with PBS containing 4% PFA for 10 minutes, and processed for immunofluorescence 
analysis as described in the paragraph 2.11. 
 
2.13 Cyst formation and drug testing in 3D culture system  
After 2 days of culture, MDCK cell-derived tubules were harvested from PDMS 
microscaffold cavities through gentle suction with a 200 l micropipette (Gilson), washed 
in PBS for 10 minutes, embedded within 200 l of 2.4 mg/ml rat-tail collagen type I, and 
finally transferred onto polyester Transwell membranes (0.4 m pore size) in 12-well 
plates (CC3460; Corning-Costar, MA, USA). Following collagen polymerisation (35-40 
minutes at 37°C), 1.5 ml of culture medium, composed of MEM supplemented with 10% 
FBS, 1% L-glutamine and 1% Pen Strep, was added. To induce cyst formation, samples 
were cultured in culture medium supplemented with 10 M forskolin (F6886; Sigma-
Aldrich) for 7 days. Next, ‘polycystic’ tubules were cultured in the presence of 102 M 
Octreotide acetate (OCTR) (0239950; Toronto Research Chemicals, Brisbane Rd, North 
York, Canada), 102 M Pasireotide diaspartate (PAS) (kind gift from Novartis Farma 
S.p.A., Varese, Italy), 104 M 2-Deoxy-D-glucose (2DG) (D6134; Sigma-Aldrich), 10 
g/ml berberine chloride (B3251; Sigma-Aldrich), 0.5 M Rapamycin (R0395; Sigma-
Aldrich), or with 10-2 M Arginine Vasopressin (AVP) (V9879; Sigma-Aldrich) alone or 
in combination with 10-2 M Tolvaptan (T7455; Sigma-Aldrich) for another 7 days. 
Control samples were maintained in culture medium alone for all 14 days. In each culture 
condition, culture medium was changed every 2 days. After fixing, tubules were harvested 
by gently cutting the surrounding collagen gel with insulin-needles under a 
stereomicroscope, and were processed for immunofluorescence and histological analysis as 
described in the paragraphs 2.10 and 2.11. The number of cysts was quantified in different 
fields of haematoxylin and eosin-stained tubules using ImageJ software. Haematoxylin and 
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eosin staining images were acquired with AxioImager Z2 microscope (Carl Zeiss). The 
area of each field was calculated using AxioVision 4.8 software (Carl Zeiss). Data are 
expressed as number of cysts/mm2. Two independent scientists performed quantification 
analyses in blind. According to the manufacturer’s indications, both forskolin, rapamycin, 
Tolvaptan and berberine were reconstituted in DMSO; OCTR and PAS were reconstituted 
in sterile saline solution; and AVP and 2DG were resuspended in sterile distilled water. 
Once in solution, compounds were diluted in culture medium to achieve the desired final 
concentration. The final DMSO concentration in the culture media never exceeded 0.1%. 
 
2.14 3D culture experiments for human developmental studies  
Fragments of about 0.6 mm in width x 4.0 mm in length of 2-day cultured hiPSC-derived 
macrotubules were transferred to polyester Transwell membranes as described in the 
paragraph 2.13. To obtain fragments of the appropriate size, tubules harvested from PDMS 
scaffolds were manually cut using insulin-needles. E13.5 CD1 mouse kidneys were freshly 
isolated as previously described (Xinaris et al., 2012, 2016). For 3D co-culture 
experiments, four E13.5 kidneys were placed within collagen in close proximity to each 
tubule and, after collagen polymerisation, culture medium [Advanced DMEM (12491023; 
Invitrogen) supplemented with 2% embryonic stem cell FBS (16141079; Invitrogen), 1% 
L-glutamine and 1% Pen-Strep] was added. Other samples were cultured in Advanced 
DMEM supplemented with 1 g/ml heparin (VERACER, Medic Italia S.r.l., Roma, Italy) 
and with different combinations of the following growth factors: 40 ng/ml HGF, 100 ng/ml 
GDNF, 200 ng/ml FGF1 (100-17A; PeproTech) and 100 ng/ml FGF7 (100-19; 
PeproTech). Both heparin and growth factors were reconstituted and stored following the 
manufacturer’s instructions, and diluted in culture medium to achieve the desired final 
concentration indicated above. Cultures were monitored by light microscopy for up to 2 
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days without changing the medium, and eventually fixed and processed for 
immunofluorescence analysis as described in the paragraph 2.11. Bright-field images of 
tubules cultured in the different aforementioned conditions were acquired with Primo Vert 
inverted microscope (Carl Zeiss). The total budding events of the human UB-like tubules 
were quantified using ImageJ software. Two independent scientists performed 
quantification analyses in blind. Data are expressed as percentage of ramified buds over 
total buds that emerged from human tubules.  
The IRCCS - Istituto di Ricerche Farmacologiche ‘Mario Negri’ adheres to the principles 
set out in the following laws, regulations, and policies governing the care and use of 
laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorisation n.19/2008-A 
issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and 
Policies providing internal authorisation for persons conducting animal experiments 
(Quality Management System Certificate - UNI EN ISO 9001:2008 - Reg. N° 6121); the 
NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives 
and guidelines (EEC Council Directive 2010/63/UE). The Statement of Compliance 
(Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of 
Laboratory Animals has been recently reviewed (9/9/2014) and will expire on September 
30, 2019 (Animal Welfare Assurance #A5023-01).  
 
2.15 Statistical analyses  
Samples were randomly allocated in every experimental groups/conditions and no 
inclusion/exclusion criteria were used. Statistical analysis was performed using 
GraphPad Prism software, version 7 (GraphPad, San Diego, CA, USA). When two 
conditions were compared, two-tailed Student’s t-test was used. When more than two 
conditions were compared, one-way ANOVA with the Tukey’s multiple comparisons test 
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(for cyst quantification) and with the Holm-Sidak’s multiple comparisons test (for ramified 
over total buds quantification) was used. Differences were considered to be significant 
when P < 0.05. Data are expressed as means ± s.e.m. See figure legends for details on 
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Catalogue number Gene symbol Description 
Hs00742896_s1 OCT4 H. sapiens POU class 5 homeobox 1 
Hs00602736_s1 SOX2 H. sapiens SRY (sex determining region Y)-box 2 
Hs02387400_g1 NANOG H. sapiens NANOG homeobox 
Hs00610080_ml T H. sapiens T, brachyury homolog 
Hs00232144_m1 LHX1 H. sapiens LIM homeobox 1 
Hs01057416_m1 PAX2 H. sapiens paired box 2 
Hs00231122_m1 GATA3 H. sapiens GATA binding protein 3 
Hs04187556_m1 HOXB7 H. sapiens homeobox B7 
Hs99999909_m1 HPRT1 H. sapiens hypoxanthine phosphoribosyltransferase 1 
Hs02758991_g1 GAPDH H. sapiens glyceraldehyde-3-phosphate dehydrogenase 
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3.1 Design and fabrication of 3D-printed PDMS scaffolds 
In collaboration with NanoMed Labs (University of Genova, Italy) and relying on the 
physiological structure of the UB tree during early kidney development (Lin et al., 2003; 
Watanabe and Costantini, 2004; Lindström et al., 2015), we designed three basic patterns 
shaped to resemble some UB segments. These patterns consisted of: a straight line 
(Supplementary Figure 1a) for UB trunks, a terminal 80° bifid branch (Supplementary 
Figure 1b) and asymmetric lateral 30° branches (Supplementary Figure 1c), both for UB 
ramifications. To mimic advanced stages of UB branching morphogenesis, we merged the 
80° and 30° basic schemes into a ramified pattern (Supplementary Figure 1d). Moreover, 
to quickly and routinely design fractal-like ramifications similar to those observed in early 
kidney development (Lin et al., 2003), we developed a ‘golden fractal tree’ (GFT) formula 
(Supplementary Figure 1e). Unlike the previously described GFTs with a constant 
amplitude (Taylor, 2007; Pons, 2013), our formula allows progressive narrowing of 
bifurcations for an infinite number of times, preventing branch overlapping 
(Supplementary Figure 1f). Finally, with the aim of engineering numerous individual 
tubules at the same time, we designed a linear multichannel pattern (Supplementary 
Figure 1g). Thereafter, we converted the custom-designed patterns into plastic masters 
through rapid prototyping technologies and 3D printing, and used them as moulds to 
produce polydimethylsiloxane (PDMS) replicas (Figure 5a). PDMS is a silicon-based 
organic polymer with numerous desirable properties that make it suitable for cell biology 
studies. In particular, PDMS is biocompatible, non-toxic to cells, chemically inert, gas 
permeable, and optically transparent for imaging applications (Briganti et al., 2006; Adler 
et al., 2010; Young and Beebe, 2010; Markov et al., 2014).  
Given their distinct geometries, we refer to the replicas with bigger, linear and ramified 
cavities as ‘macro-scaffolds’, and those with multiple micro-patterned linear cavities as 
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‘micro-scaffolds’. Differently from typical PDMS devices made for cell cultures, which 
are pre-treated to possess hydrophilic properties and adhesive surfaces (Halldorsson et al., 
2015), our scaffolds were kept hydrophobic to facilitate detachment of engineered tissues 
without compromising cell-ECM seeding, and to enable standard sterilisation processes so 
that the scaffolds could be reused.  
 
3.2 Engineering kidney tubular structures with different geometries by seeding 
epithelial cell suspensions into PDMS scaffolds 
To develop and optimise our system for tubule engineering, we used the MDCK epithelial 
cell line, which is composed of both distal tubule and collecting duct cells (Rindler et al., 
1979; Herzlinger et al., 1982), and has been widely used in studies examining cyst and 
tubule formation. Collagen type I was chosen as ECM-mimicking gel in which to 
resuspend the cells as it is the most abundant ECM component, can store and support 
diffusion of nutrients and growth factors, permits 3D intercellular interactions, and 
provides structural support for cell movement and organisation into tissues (Davies, 2001).  
With the aim of engineering epithelial kidney tubules, a range of 0.7-6.5x105 MDCK 
cells/µl collagen were seeded into PDMS scaffold cavities, and cultured for up to 2 days 
(Figure 5b). In accordance with previous studies, tubulogenesis was induced by 
supplementing culture medium with 40 ng/ml hepatocyte growth factor (HGF), a molecule 
capable of strongly inducing in vitro branching tubulogenesis (Montesano et al., 1991b, 
1991a; Sakurai et al., 1997; Pollack et al., 1998; Liu et al., 2007). The seeding conditions 
with the highest rate of tubule formation (94% of total seeded scaffolds) were 1.2x105 and 
2x105 cells/µl collagen for macro- and micro-scaffolds, respectively (Figure 5c-e and f). It 
is important to know that, in the remaining cell concentrations tested, only cell clustering 
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was observed within the scaffolds’ cavities and no tubules developed (Supplementary 
Figure 2a and b). 
Under the aforementioned conditions, three hours post-seeding, dispersed cells organised 
to give rise to tubular structures with analogous size and shape to the scaffold’s cavity 
(Supplementary Figure 2c). At day 1, single and branched structures noticeably shrank 
and began detaching from the moulds (Figure 5c). At day 2, the shrinkage increased and 
whole intact branches emerged autonomously from the cavity. Strikingly, at bifid 
branching points, a presumptive luminal space was observed through bright-field 
microscopy and appeared as a translucent region delimited by darker edges. This suggested 
that a common cavity between tubular structures was forming (Figure 5c). Using PDMS 
scaffolds with more complex geometries, we successfully applied our method to engineer 
increasingly branched and tree-like tubular structures (Figure 5d and e). By seeding cells 
into multichannel scaffolds with micro-patterned linear cavities, we concomitantly 
obtained multiple individual linear microtubules within 2 days of culture (Figure 5f), thus 
demonstrating the applicability of our system on a micro-scale.  
Depending on scaffold size, we refer to the tubular structures generated and depicted in 
Figure 5c-e and Figure 5f as ‘macrotubules’ (both single and in networks) and 
‘microtubules’, respectively.  
 
3.3 Engineered tubules undergo rapid lumen formation and epithelial polarisation  
Development of mature epithelial tubules involves cell rearrangements that lead to the 
formation of a lumen enclosed by an epithelium with appropriate polarisation (Andrew and 
Ewald, 2010). Kidney tubules consist of aligned epithelial cells, which adhere by means of 
specialised intercellular junctions and lie on a basement membrane, giving rise to a 
monolayered epithelium enclosing a central lumen. This configuration entails that cells 
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acquire a well-established apical-basal polarity, with apical membranes facing the lumen, 
and lateral and basal membranes in contact with neighbouring cells and basement 
membrane, respectively (Bryant and Mostov, 2008; Andrew and Ewald, 2010).  
To examine the presence of a lumen and evaluate the establishment of a polarised 
epithelium, we immunostained the engineered microtubules and analysed them from the 
surface to the inner region through confocal Z-stack imaging. Remarkably, this analysis 
revealed the presence of a single lumen surrounded by a monolayer of epithelial cells 
positive for E-cadherin (Figure 6a). This transmembrane glycoprotein is abundantly 
expressed in distal tubule, collecting duct and most medullary segments, where it plays an 
important role in the establishment of intercellular adherens junctions and renal epithelial 
polarity (Prozialeck et al., 2004). Identically to microtubules, branches from macrotubular 
systems possessed well-established epithelial structures with a coalesced lumen. In 
particular, the lumen was lined by tubular walls consisting of a monolayer of cells  
showing aligned nuclei, positivity for E-cadherin in the lateral membranes and wheat germ 
agglutinin (WGA)-lectin in the basement membranes, (Figure 6b). Some cells of the 
tubular walls were positive for peanut agglutinin (PNA)-lectin - a known MDCK cell 
luminal surface marker (Schumacher et al., 2008) - and podocalyxin - an integral 
membrane protein expressed in the apical domain of terminally polarised MDCK cells – in 
the apical membranes (Meder et al., 2005) (Supplementary Figure 3a).  
Overall, these findings proved that we were successful in engineering tubules consisting of 
a properly apical-basal polarised monolayered epithelium lining a continous lumen. 
Apoptosis is one crucial step underlying lumen formation during tubulogenesis. In tubule 
primordia, cells that are not in direct contact with ECM undergo programmed cell death 
generating an empty space, namely the lumen. Hence, this process gives rise to a tubule. 
Considering the timely occurrence of this phenomenon, engineered tubules were examined 
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at an earlier stage of development, providing insight into the mechanism of lumen 
formation in our system. Haematoxylin staining of cross-sectioned 1-day macrotubules 
showed that these had a major lumen enclosed by a peripheral layer of cells with nuclei 
aligned along the tubular walls. In macrotubules, centrally located cells featured chromatin 
condensation and immunoreactivity for cleaved caspase 3 (Supplementary Figure 3b and 
c respectively), both clear signs of apoptosis. By contrast, peripheral cells constituting 
tubular walls revealed normal cell morphology and no signs of apoptosis (Supplementary 
Figure 3c). These findings implied that, in our system, cells in the central region of the 
tubular aggregate die by apoptosis, creating a hollow, eventually giving rise to the lumen 
by a process known as cavitation (Schumacher et al., 2008; Sigurbjörnsdóttir et al., 2014).  
In control experiments, in which cells were cultured in the absence of HGF, phenotypically 
compact tubules did indeed form, but could not develop a lumen (Supplementary Figure 
3d). 
 
3.4 Engineered tubules exhibit macromolecule absorption and organic anion 
transport capacities 
The mature renal tubular epithelia reabsorb macromolecules, and control the excretion of 
endogenous compounds, xenobiotics and organic anions. It has been previously described 
that both medullary and cortical collecting duct cells are capable of dextran macromolecule 
internalisation from their basolateral surfaces (Schwartz and Al-Awqati, 1985; Raghavan 
et al., 2014). Organic anion transepithelial transport and excretion into the lumen are 
mediated by specific organic anion transporters (OATs) widely distributed across kidney 
tubules. Specifically, these localise to both the basolateral and apical membranes of 
proximal tubule as well as collecting duct epithelial cells (Kojima et al., 2002; Sweet et al., 
2006; Yokoyama et al., 2008; Burckhardt, 2012).    
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Therefore, to test whether the engineered microtubules possessed such functional 
properties, we soaked them in solutions containing either fluorescein isothiocyanate-
conjugated (FITC)-dextran (molecular weight 10 kDa) or the tracer anion 6-
carboxyfluorescein (6CF) (Sweet et al., 2006). The latter has better kinetic properties than 
fluorescein for investigating cellular OAT-mediated transport, due to its additional 
negative charge that, in comparison, causes increased cell retention (De Clerck et al., 
1994). 
Immunofluorescence analysis showed that dextran was internalised abundantly in the 
central areas of the microtubules (Figure 6c) and in the cytoplasm of cells of the tubular 
surface (Figure 6c, inset). With regards to 6CF, it was transported through the tubular 
epithelium and then secreted into the peripheral regions of the lumen (Figure 6d). 
Moreover, some E-cadherin-positive cells confined to the tubules’ wall, internalised 6CF 
and retained it within their cytoplasm (Figure 6d, inset). When we soaked tubules in the 
presence of both 6CF and probenecid - a potent and broad inhibitor of the OAT system 
(Nagle et al., 2011; Nigam et al., 2015) - fluorescent signal was no longer detectable, 
neither in the cells nor in the lumen (Figure 6e). These findings demonstrated that 
engineered tubules displayed absorption and transport characteristics typical of collecting 
duct epithelia, as they appear capable of macromolecule internalisation and organic anion 
transport through the OAT-mediated process.  
 
3.5 Using engineered tubules as a tool to model polycystic kidney disease (PKD) 
PKD is one of the most frequent genetic disorders (the fourth leading cause of CKD 
resulting in ESRD in the USA), affecting about 7 million people worldwide and accounting 
for 7%-15% of patients on RRT (Akoh, 2015; Saigusa and Bell, 2015). It is characterised 
by the development of fluid-filled epithelial cysts within kidney tubules in a cAMP-
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dependent fashion. Unfortunately, at present, there is no effective therapy for PKD (Ong et 
al., 2015). 
When cultured in a 3D ECM environment in the presence of cAMP elevating agents, 
MDCK cells can form individual epithelial cysts (Mangoo-Karim et al., 1989; Li et al., 
2004), as the in vivo models of PKD (Gattone et al., 2003; Torres et al., 2004; Wang et al., 
2005). For these reasons, they have been extensively used to model PKD and explore the 
effects of drugs on cyst development. However, in vitro cultures of individual cysts do not 
replicate the gradual expansion of cysts that occurs in PKD, and substantially differ from 
the physical and biochemical conditions of the tightly packed cysts within the polycystic 
tubules.  
We decided to test whether our system, allowing the engineering of kidney epithelial 
tubules, could provide an efficient tool to generate polycystic tubules that better replicate 
pathological tissue phenotype in vitro. To this aim, we transferred microtubules to a 3D 
collagen culture system and stimulated them with forskolin for 7 days. Forskolin is a 
compound that has previously been shown to increase intracellular cAMP levels and 
induce cyst development in vitro and in vivo (Balkovetz, 1998; Sullivan et al., 1998; Li et 
al., 2004) (Figure 7a). At day 14, both macroscopic and histological examination showed 
that forskolin-treated tubules developed numerous translucent spheroidal cysts along the 
whole length of the tubule (Figure 7b). Immunofluorescence analysis confirmed that 
numerous round-shaped cysts formed homogeneously throughout the tubule (Figure 7c). 
Cysts were circumscribed by a monolayer of cells positive for E-cadherin in the basolateral 
membranes, and podocalyxin in the apical membranes, demonstrating the presence of 
polarised cysts within tubules (Figure 7d). Remarkably, cyst formation disrupted tubular 
epithelial organisation and caused lumen loss. Overall, these features appear similar to in 
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vivo PKD pathophysiology (Martinez and Grantham, 1995; Grantham, 1996; Torres and 
Harris, 2006), indicating that engineered tubules efficiently model PKD.  
 
3.6 Using engineered polycystic tubules for drug testing and discovery studies 
One major aspiration in designing this system was to provide a novel tool for drug testing 
and discovery studies in vitro. To this purpose, we examined whether forskolin-stimulated 
tubules would respond to pharmacological treatment to inhibit cyst formation by 
comparing the effect of compounds with different mechanisms of action on cyst 
regression.  
We, therefore, treated forskolin-stimulated tubules for 7 days with: (i) rapamycin - an 
inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is aberrantly 
activated in cystic epithelia leading to cystic cell hyperproliferation and marked 
cystogenesis (Shillingford et al., 2006; Serra et al., 2010); (ii) tolvaptan - a highly selective 
arginine vasopressin (AVP) V2 receptor antagonist, which inhibits the overactivated AVP 
signalling for intracellular cAMP production, cell proliferation, transepithelial fluid 
secretion, and cyst growth in PKD collecting ducts and distal nephrons (Reif et al., 2011; 
Blair and Keating, 2015); (iii) octreotide (OCTR) and pasireotide (PAS) - somatostatin 
analogues that reduce intracellular cAMP levels, cell proliferation and cystogenesis in in 
vitro and in vivo experimental models, with different specificity and binding affinity to 
somatostatin receptors (Masyuk et al., 2007, 2013); (iv) 2-deoxy-D-glucose (2DG) - a 
glucose analogue that ameliorates disease progression in vivo by competing with glucose 
thereby blocking aerobic glycolysis in PKD cells (Rowe et al., 2013; Priolo and Henske, 
2013; Chiaravalli et al., 2016); and (v) berberine - an isoquinoline quaternary alkaloid 
isolated from Chinese medicinal herbs, with anti-proliferative effect, mainly linked to cell 
cycle arrest at G0/G1 phase (Bonon et al., 2013), and able to inhibit the  mitochondrial 
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oxidative phosphorylation resulting in ATP depletion (Fan et al., 2013). This compound 
has never been studied in a PKD model.  
We performed immunofluorescence staining to evaluate the effect of tested compounds on 
cyst regression; in parallel, we carried out cyst quantification on haematoxylin and eosin 
stained tubules. These analyses demonstrated that rapamycin treatment had no significant 
effect on reducing cyst number compared to forskolin-stimulated tubules (controls) 
(Figure 7e and k). To test the effect of Tolvaptan, we treated forskolin-stimulated tubules 
with AVP alone, or in combination with Tolvaptan (Reif et al., 2011). As expected, 
treatment with AVP alone increased cyst number, while administration of AVP in 
combination with Tolvaptan significantly decreased cyst size and number (63%) (Figure 
7f and l) (Reif et al., 2011). Moreover, cyst number significantly diminished when tubules 
were treated with OCTR (58%) (Figure 7g and k) and PAS (43%) (Figure 7h and k) 
compared to controls. Notably, 2DG and berberine were the most effective compounds for 
cyst regression, reducing the number of cysts by 71% and 72%, respectively (Figure 7i-k), 
and limiting cysts to the peripheral areas of tubules. An outstanding difference observed 
between the treatments was the drugs’ ability to restore both the tubular central lumen and 
epithelial organisation. Indeed, only 2DG and berberine possessed this ability (Figure 7i 
and j), whereas Tolvaptan, OCTR and PAS did not, even though they reduced cyst 
numbers to various extents, (Figure 7f-h). Together these data demonstrate that engineered 
‘polycystic’ tubules responded to drug treatments in a quantifiable manner, making this 
system a valuable tool for drug testing and discovery studies. Furthermore, we revealed the 
anti-cystogenic properties of berberine in polycystic kidney tissue, making it a promising 
new drug with therapeutic potential for PKD treatment. 
 
  CHAPTER 3 - RESULTS 
66 
 
3.7 Engineering functional human epithelial tubules starting with hiPSC-derived UB-
like progenitor cells 
The next goal was to test our system’s ability to efficiently engineer human tubules, using 
hiPSCs previously generated in our laboratory through lentiviral-mediated reprogramming 
of somatic cells (Imberti et al., 2015). First, we directed the differentiation of the hiPSCs 
into UB-committed renal progenitor cells through 4-day exposure to chemically defined 
media as previously described by Belmonte group (Xia et al., 2013). This differentiation 
protocol consists of a first step of mesoderm commitment and a second step of UB fate 
induction (Xia et al., 2014). As expected, differentiating cells displayed a temporal gene 
expression pattern similar to that obtained by Xia and colleagues, which corresponded to 
mesoderm and IM commitment, and eventually UB-like progenitor cell differentiation 
(Supplementary Figure 4). Once the differentiation protocol had been optimised, we 
resuspended cells obtained from 2 to 4 days of differentiation in collagen, and seeded them 
into PDMS scaffolds according to the 3D culture settings and tubulogenic conditions 
established for MDCK cells (Figure 8a). Although 3- and 4-day differentiated cells 
generated compact tubular structures, the exposure to HGF alone was not sufficient to 
induce formation of monolayered epithelia surrounding a single lumen (Supplementary 
Figure 5a). To overcome this problem, we modified culture conditions by enriching the 
medium with glial cell-derived neurotrophic factor (GDNF), a molecule secreted by the 
MM that is essential for UB formation, growth and branching during kidney development 
(Shakya et al., 2005). After 2 days in these culture conditions, immunofluorescence 
analysis of tubules derived from 3- and 4-day differentiated hiPSCs showed the formation 
of a continous lumen (Figure 8b and c) delimited by a monolayer of cells positive for 
WGA-lectin and E-cadherin in the basolateral membranes (Figure 8b). A fraction of the 
cells expressed the apical epithelial marker protein kinase C-ζ (PKC-ζ) (Yang et al., 2013) 
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in the apical membranes (Supplementary Figure 5b). Neither undifferentiated hiPSCs, 
used as controls, nor 2-day differentiated cells were able to form tubular structures 
(Supplementary Figure 5c and d).  
Finally, to test whether this maturation degree would reflect UB-associated functions, we 
soaked engineered human microtubules in a solution containing FITC-dextran or 6CF. 
Confocal microscopy analysis revealed massive dextran internalisation throughout the 
tubular lumen (Figure 8d) and 6CF transport visible as a patchy signal in the cytoplasm of 
peripheral cells (Figure 8e), both functional features typical of in vitro-cultured UB. 
Similarly to MDCK tubules, at day 1, human tubules had many apoptotic cells, positive for 
cleaved caspase 3 and displaying condensed chromatin, at the centre of cross-sectioned 
macrotubules, confirming that cavitation is the mechanism of tubular lumen formation 
(Supplementary Figure 5e and f). 
To assess the reproducibility of our system, we engineered tubules from a hiPSC line 
obtained in our laboratory through a different technology, the Sendai virus-mediated 
expression of reprogramming factors in healthy donor-derived peripheral blood 
mononuclear cells (Ciampi et al., 2016). Both hiPSC differentiation towards UB 
progenitor-like cells and UB-like tubule engineering were successful (Supplementary 
Figure 6). Altogether, these data demonstrate that our innovative system is strongly robust 
and reproducible in that it allows successful production of human UB-like tubules from 
several hiPSC lines.  
 
3.8 Using human tubules as a tool for studying UB developmental processes and 
defects  
One of the greatest limitations in studying the developmental processes and disorders of 
human kidney is the scarcity of human embryonic samples and the lack of methods for 
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engineering kidney tissue or units from patients with genetic mutations. In virtue of our 
establishing a technology able to provide human UB-like tubules, we decided to 
investigate first whether they exhibited developmental capacities. Next, we evaluated the 
possibility of using the engineered tubules to examine both human UB morphogenetic 
mechanisms and possible developmental anomalies associated with genetic disorders. 
 
3.8.1 Engineered human tubules recapitulate early steps of UB morphogenesis following 
mouse embryonic kidney induction or by exposure to selected growth factors 
During the early developmental stages, the UB undergoes rapid budding and branching 
events, which mainly consist of iterative lateral ramifications and terminal bifid 
bifurcations (al-Awqati and Goldberg, 1998; Shah et al., 2004; Nigam and Shah, 2009; 
Costantini and Kopan, 2010). Although during kidney development the MM is involved in 
inducing and regulating UB branching pattern through direct contact, the ability to 
elongate and branch is intrinsic to the UB epithelium. Indeed, these processes can also take 
place without direct contact with MM, in the presence of soluble growth factors and ECM 
components (Qiao et al., 1999a).  
Thus, we tested whether engineered human tubules possessed UB developmental 
properties and would respond to kidney developmental cues. Firstly, we co-cultured 
macrotubules into a 3D collagen culture system with mouse embryonic kidneys as sources 
of soluble factors to stimulate UB morphogenesis (Figure 9a). At day 1, bright-field 
microscopy showed primary buds emerging from the main body of the tubule. At day 2, 
lateral ramifications emerged from elongated primary buds, leading to the formation of 
secondary buds (Figure 9b). Immunofluorescence analysis revealed that these buds 
consisted of multicellular cords of epithelial cells with aligned nuclei and expressing E-
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cadherin (Figure 9c). This configuration represents an early step of tubulogenesis in vitro 
(Sakurai et al., 1997). 
Secondly, we assessed the effect of different combinations of selected growth factors 
known to be involved in rodent UB morphogenesis (Qiao et al., 1999a, 1999b, 2001; 
Shakya et al., 2005) on inducing human tubule budding. The basal culture condition with 
HGF and GDNF induced 35.05 ± 1.02% of ramified buds in the total budding events 
(Figure 9d). Addition of FGF1 - a strong inducer of UB branching and stalk formation 
(Qiao et al., 2001) - or FGF7 - a stimulator of UB survival and growth in vitro (Qiao et al., 
1999b, 2001) - to the basal culture condition did not significantly increase the percentage 
of ramified buds (41.11 ± 10.60% and 52.38 ± 6.24%, respectively) (Figure 9d). 
Conversely, when all growth factors were used together, the number of ramified buds 
markedly increased (71.96 ± 3.22%) (Figure 9d-f) and was comparable to that observed in 
co-culture with mouse embryonic kidneys (74.81 ± 4.12%) (Figure 9b and d). 
Remarkably, when all growth factors were added in combination, a fraction of ramified 
buds displayed terminal bifid bifurcations (Figure 9e).  
Overall, these data indicate that engineered human tubules are capable of recapitulating 
early steps of UB morphogenesis, thus providing a valuable tool for studying the 
mechanisms of human UB development.  
 
3.8.2 Investigating UB developmental defects in tubules engineered using hiPSCs 
derived from a patient with a heterozygous PAX2 mutation 
Taking advantage of engineered human tubules’ developmental capacities, we next applied 
our system to study possible defects in UB morphogenesis using Paired box 2 (PAX2) 
mutated cells. PAX2 gene is highly expressed during early kidney developmental stages in 
both condensing MM and branching UB (Dressler et al., 1990; Eccles et al., 1995; Dressler 
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and Woolf, 1999). It has been previously described that heterozygous PAX2 mutations 
cause reductions in UB branching and nephron number in vivo (Harshman and Brophy, 
2012), indicating that a direct relationship exists between UB branching and nephron 
induction.  
We therefore derived hiPSCs from a patient with a heterozygous PAX2 mutation (Barua et 
al., 2014) through Sendai virus-mediated reprogramming of somatic cells (Supplementary 
Figure 7). Pluripotency was confirmed by evaluating the expression of pluripotency 
transcription factors (OCT4, NANOG and SOX2) and hESC surface markers (SSEA-3, 
SSEA4, TRA-1-60 and TRA-1-81), and the specification into the three germ layers 
(Supplementary Figure 7a-c). Moreover, reprogrammed cells showed a normal karyotype 
of 46,XY (Supplementary Fig. 7d). Having confirmed the pluripotent state, we 
successfully differentiated patient-derived hiPSCs towards UB progenitor-like cells, and 
engineered patient-derived UB-like macrotubules (Supplementary Figure 8). The latter 
were cultured in the presence of all selected growth factors as mentioned above (Figure 9h 
and i), and alongside healthy donor-derived tubules, used as controls (Figure 9e and f). 
Strikingly, under these culture conditions, patient-derived tubules were capable of 
developing almost exclusively primary buds (Figure 9h), as opposed to the numerous 
ramified buds seen in healthy donor-derived tubules (Figure 9e). It is also worth noting 
that quantification analysis disclosed a marked decrease in ramified buds in these tubules 
compared with controls (Figure 9g). These results are in agreement with previous in vivo 
data indicating that heterozygous mutation in the PAX2 gene caused paucity in UB growth 
and significant reduction in UB branching (Porteous et al., 2000; Eccles et al., 2002). 
Overall, this proves the effectiveness of our system for studying developmental defects in 
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In the present study, we have developed a novel technology for engineering functional 
custom-made complex kidney epithelial tubules by 3D-printed PDMS scaffolds using 
different cell types. We first began by creating tubules of varying sizes and shapes with the 
MDCK cell line, which is derived from adult distal tubule/collecting duct epithelia. The 
engineered tubules were endowed with a single lumen enclosed by a monolayer of oriented 
and polarised cells exhibiting transport properties typical of mature renal tubular epithelia. 
We successfully employed engineered tubules to model PKD and screen for several 
anticystogenic drugs. Then, we refined our system in order to engineer functional hiPSC-
derived UB-like tubules and used them as a tool for investigating human kidney 
developmental mechanisms and patient-specific defects. 
Previous studies documented the development of engineering systems that, by exploiting 
the renal progenitor cells’ self-assembly potential in vitro, were able to yield 3D tubular 
structures. However, these systems have important limitations that made them 
inappropriate to generate kidney tubular units suitable for engineering a functional and 
anatomically correct kidney tissue. Relying on cell-driven assembly, these technologies 
lack control over the tubular structure formation, as tubulogenesis occurred through chaotic 
and geometrically uncontrolled cell organisation in 3D ECM-based cell cultures (Barros et 
al., 1995; Sakurai et al., 1997; Yuri et al., 2017). Consequently, instead of developing with 
precise architectural frameworks, engineered tubules were highly heterogeneous in size 
and shape.  
Other kidney tubule engineering systems were based on cell seeding into 3D-printed 
scaffolds with pre-defined geometries (MacKay et al., 1998; Humes et al., 1999; 
Schumacher et al., 2008; Shen et al., 2013, 2015, Jansen et al., 2015, 2016; Homan et al., 
2016). In particular, tubule formation arose from cell seeding into hollow cylindrical-
shaped scaffolds with pre-coated inner surfaces to which cells adhered and grew up to form 
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a confluent monolayer. Thus, no cell self-assembly into tubular epithelia took place 
(MacKay et al., 1998; Humes et al., 1999; Schumacher et al., 2008; Shen et al., 2013, 
2015, Jansen et al., 2015, 2016; Homan et al., 2016), as instead occurs in vivo when cells 
are embedded in a 3D ECM environment in the presence of tubulogenic conditions. In 
spite of their unnatural formation, these bio-artificial renal tubules were still exploited for 
functional and toxicological studies (MacKay et al., 1998; Humes et al., 1999; Shen et al., 
2013, 2015, Jansen et al., 2015, 2016; Homan et al., 2016). The shared inability in 
reproducing the in vivo epithelial tubulogenesis is a limitation we have overcome by 
developing a system that, relying on cell self-assembly into epithelial tubules, yields renal 
tissues more fitting for functional and pharmacological investigations.  
Most of these systems share an additional drawback: the epithelial tubular structures 
cannot be physically removed from the surrounding ECM or from the pre-formed 3D-
printed scaffolds in which they formed. This prevents tubules from being used for further 
investigations, such as morphogenetic studies and kidney tissue engineering experiments.   
On the other hand, our technology allows engineering tubules with lumen, predefined 
geometries, resembling foetal UB/collecting duct epithelia’s architecture and functions, 
which can be easily removed from the scaffolds. We engineered kidney tubular units in a 
controlled fashion by seeding cells, which were previously resuspended in collagen gel, 
into the 3D-printed PDMS scaffolds’ cavities and exposing them to appropriate 
tubulogenic stimuli. Under these conditions, similar to those in vivo, cells are directed to 
self-assemble into geometrically defined epithelial tubules within a 3D ECM-mimicking 
environment. The fact that our engineered tubules can be harvested, handled and 
transferred to different experimental conditions makes our system a valuable platform for 
several applications, such as kidney disease modelling, drug testing and discovery, as well 
as developmental studies. 
  CHAPTER 4 - DISCUSSION 
74 
 
In tissue engineering, the nature of the biomaterials’ surface and the biostructures’ 
complexity play a pivotal role for establishing realistic diagnostic and therapeutic 
solutions. In our system, we decided to fabricate hydrophobic PDMS scaffolds. This 
technical expedient was key to enable the development of complex tubular structures. 
Indeed, the scaffold cavities’ hydrophobicity allowed cell-collagen mixture gathering and 
immobilisation, thus limiting the risk of cell and ECM dispersal, and precluded irreversible 
cell adhesion and collagen attachment. Hence, PDMS hydrophobicity indirectly endorsed 
cell movement and spatial organisation in order to generate functional complex kidney 
tubules for studying development, modelling disease and investigating therapeutic 
approaches.  
To rapidly prototype more complex structures with truly biomimetic features (Díaz 
Lantada et al., 2013) we developed a mathematical model that can provide fractal-like 
geometries. This ‘Golden Fractal Tree’ model maximised the amount of matter that can 
suit a limited surface, such as that of the scaffolds’ cavities, and allow progressive 
narrowing of bifurcations an infinite number of times. This avoids branch overlapping, a 
clear advantage for the serial production of reproducible complex tissues. Furthermore, our 
PDMS scaffolds can be reused upon conventional sterilisation techniques without requiring 
any other kind of treatment, thus providing an additional technical advantage.  
Since kidney tubulogenesis is a biological process modulated by interactions between 
epithelial cells, soluble factors and the surrounding ECM components (Santos and Nigam, 
1993), we first determined the precise ECM concentration that will allow for cell viability, 
growth, movement, establishment of cell-ECM and cell-cell adhesion, and organisation 
into tissue. Based on data published by Hauser et al., (Hauser et al., 2016) we selected the 
collagen type I concentration of 2.4 mg/ml. This concentration was described as the most 
efficient for tubule formation compared to lower ones, whereas higher concentrations 
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caused collagen gel to become too much rigid, thus preventing cell organisation and, 
concomitantly, tubulogenesis. Even in our system, the use of collagen at a concentration of 
2.4 mg/ml has proved to be effective for tubule engineering; hence, we adopted this 
condition for our protocol.  
Although tubular structures seemingly formed at a given cell number per collagen volume, 
a polarised epithelium and lumen were established only in the presence of HGF, a growth 
factor previously used to modulate cell growth and motility, and induce kidney 
morphogenetic processes in various epithelial cell lines (Santos and Nigam, 1993; 
Nakamura et al., 1997; Maeshima et al., 2000). Unlike previous methods that require long-
term cultures - often ranging from 7 to 15 days (Sakurai et al., 1997; Schumacher et al., 
2008; Hauser et al., 2016) - our highly efficient method produced epithelial tubules with 
lumen and predetermined geometries in only 2 days of culture.  
Engineered tubules displayed functional characteristic of kidney tubules (Meyer et al., 
2004; Sweet et al., 2006; Lawrence et al., 2015), such as internalisation of the synthetic 
macromolecule dextran and transporter-mediated organic anion tracer transport. These 
functional properties may be exploited in studies focussing on the mechanisms of active 
and passive trafficking of endogenous substrates and metabolites across renal tubular 
epithelial membranes, as well as transporter-mediated absorption, distribution, and 
elimination of drugs and other xenobiotics. In particular, the organic anion and cation 
transporters are broadly involved in transporting steroids, hormones and neurotransmitters, 
as well as excreting antivirals, antibiotics, chemotherapeutics and statins (Roth et al., 
2012). These transporters are, therefore, able to influence the pharmacokinetics of their 
specific drug substrates, thus playing crucial roles in the effectiveness of pharmacological 
therapies and removal of toxicants. Hence, our engineered tubules may potentially 
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constitute a powerful tool for experimental nephrology, pharmacokinetic and toxicology 
studies.  
By optimising our protocol, we successfully engineered hiPSCs-derived-UB-like tubules 
that replicated the kidney tubular epithelial architecture and functions as described above 
and, when co-cultured with mouse embryonic kidneys, underwent budding morphogenesis. 
The latter phenomenon indicated that human tubules could respond to kidney 
developmental cues in the form of soluble factors, a key aspect that made them suitable for 
elucidating mechanisms of human UB early morphogenesis. Indeed, we used the 
engineered human tubules to identify a novel combination of growth factors that is capable 
of inducing human UB-like tubules budding and ramification.  
Finally, we applied our system to investigate how budding morphogenesis is affected by a 
heterozygous mutation in the PAX2 gene through the generation of UB-like tubules from 
patient-derived hiPSCs.  
To the best of our knowledge, no other existing technology is able to engineer custom-
made, complex and functional kidney tubules with different cell sources, such as renal cell 
lines and in vitro-differentiated hiPSCs. It is also remarkable that, in our tissue engineering 
system, kidney tubules develop into patterned and polarised epithelia enclosing a lumen 
through cell spatial organisation in response to tubulogenic cues, as occurs in vivo. For 
these reasons, and since the engineered tubules can be transferred to different experimental 
conditions, we used them to model PKD, test drugs, and study human development.  
PKD is characterised by the gradual formation of plenty fluid-filled cysts in the kidney. 
Unfortunately, there are currently no approved therapies, causing this disease to remain 
incurable; the existing treatments can only help manage the wide range of problems 
associated with this condition. PKD is an inherited disorder linked to the disturbance of 
multiple intracellular pathways and cell functions, and affecting, with varying incidences, 
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both children and adults (Grantham et al., 2011; Sun et al., 2011; Sweeney and Avner, 
2011; Wallace, 2011; Willey et al., 2017). Most of children and adult patients are destined 
to experience ESRD, thus eventually requiring RRT. In PKD, the development and 
enlargement of spheroidal epithelial cysts are the consequence of aberrant cell proliferation 
in the renal tubular epithelia, accompanied by transepithelial fluid secretion into the cystic 
luminal space. The over-stimulated cell proliferation is due to increased intracellular 
cAMP levels, a second messenger that is responsible for up-regulating B-Raf/MEK/ERK 
signalling in both animal models and patients. Hence, decreasing intracellular cAMP levels 
is considered one of the most appealing approaches for ameliorating PKD outcome.  
Given the severity of the disease, the absence of in vitro and in vivo models able to 
faithfully mimic human PKD and the lack of effective therapies, it is imperative to develop 
more realistic PKD modelling systems suitable for drug screening. To begin to address this 
issue, we decided to use our collecting duct-like tubules engineered with the MDCK cells. 
These cells are known to form individual fluid-filled cysts when cultured in 3D ECM 
environments and stimulated with pharmacological agents capable of elevating 
intracellular cAMP levels. For this reason, their use in modelling PKD and exploring 
drugs’ efficacy on renal cyst regression has been extensive (Mangoo-Karim et al., 1989; Li 
et al., 2004; Gao et al., 2011). Nonetheless, conventional PKD models present one major 
drawback, namely the production of individual cysts, which cannot recapitulate the gradual 
cyst expansion into the tubular lumen as occurs in PKD in vivo. This precluded the 
possibility of modelling lumen obstruction and perturbations in both tissue architecture and 
epithelial polarisation, as well as the induction of mechanical stress and hypoxic conditions 
typical of PKD tubules. No other in vitro models can recapitulate PKD appropriately 
enough to constitute a valid alternative to conventional 3D cell cultures. Therefore, we 
decided to verify whether our engineered collecting duct-like tubules could provide a tool 
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to more realistically model PKD and perform drug testing and discovery studies. When we 
transferred the engineered collecting duct-like tubules to a 3D collagen culture system and 
stimulated them with the diterpene forskolin - a compound that induces cAMP production 
by activating several adenylyl cyclases - they developed many polarised cysts closely 
packed along the whole length of the tubules, causing lumen loss and disrupting the overall 
epithelial organisation. These features resembled bona fide those of diseased tubules in 
vivo and indicated that our engineered tubules can be used to model PKD in vitro.  
When we added Tolvaptan, OCTR, PAS, 2DG or berberine to the culture medium, cyst 
density within tubules decreased to different extents. This indicated that engineered tubules 
could be an efficient tool for quantifying the effects of different known pharmacological 
agents and novel compounds on cyst regression. 
The AVP V2 receptor antagonist Tolvaptan has been shown able to inhibit distal tubule 
and collecting duct cyst progression in both humans (Torres et al., 2012) and PKD rodent 
model (Gattone et al., 2003; Torres et al., 2004) by decreasing intracellular cAMP levels. 
According to these observations, concomitant administration of AVP - the V2 receptor’s 
ligand and the major cAMP agonist in the collecting duct (Yasuda and Jeffries, 1998; 
Wallace et al., 2001) - and Tolvaptan, following forskolin stimulation, significantly 
decreased cyst density within our tubules, when compared to the sole AVP stimulation. 
This confirmed that our PKD modelling system was applicable and reliable for drug 
screening purposes. 
The synthetic somatostatin analogues OCTR and PAS, which possess longer half-lives 
than somatostatin and inhibit cAMP production, have been tested in preclinical and clinical 
trials. It has been previously reported that OCTR, which binds to somatostatin receptor 2 
(SSTR2) and SSTR3, counteracts renal cyst growth in rodent models (Masyuk et al., 2007) 
and humans (Ruggenenti et al., 2005; Hogan et al., 2010; Caroli et al., 2013), whereas 
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PAS, which has high affinity to SSTR1, SSTR2, SSTR3 and SSTR5, was more effective 
than OCTR in mouse and rat PKD models (Masyuk et al., 2013). Conversely, in our 
system, we observed that OCTR was more effective than PAS in reducing cyst density, but 
the difference was not statistically significant. This inconsistency may be due to the 
condition in which the authors evaluated and quantified the effects of the two compounds 
on cyst growth. Since they adopted in vivo models and kept into consideration the whole 
renal parenchyma, they did not exclusively regard the kidney tubular compartment. We 
have instead investigated the drugs’ effects in vitro and solely on the engineered 
‘polycystic’ collecting duct-like tubules.  
Although in vivo studies demonstrated that treatments with Tolvaptan and somatostatin 
analogues slow PKD progression by decreasing cell proliferation and inducing cyst 
regression, severe adverse effects are associated with these pharmacological treatments 
(Riella et al., 2014). This makes the identification of novel effective therapeutic 
compounds with better tolerance an imperative need, so that many research groups are 
currently performing intense research to achieve this goal. 
Working in this direction, in the present study we showed that 2DG - a glucose analogue 
that cannot be metabolised - and berberine - a compound approved for clinical trials in 
some diseases but that has never been tested in PKD - had a robust effect on cyst 
regression and completely restored both the central lumen and tubular epithelium integrity.  
The marked cyst regression in our ‘polycystic’ tubules following 2DG treatment is in line 
with data from recent studies conducted in vitro and in in vivo models of both aggressive 
(Rowe et al., 2013) and slowly progressive (Chiaravalli et al., 2016) PKD. Rowe et al. 
demonstrated that PKD cells and mice displayed enhanced glycolysis, whereas glucose 
deprivation decreased PKD cell proliferation in vitro, and 2DG treatment ameliorated 
kidney volume, cystic index, but also reduced cell proliferation rate in vivo (Rowe et al., 
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2013). When Chiaravalli et al. treated PKD mouse models with 2DG, slower disease 
progression with both kidney/body weight and tubular and collecting duct cyst number 
reduction was observed in the absence of obvious signs of toxicity (Chiaravalli et al., 
2016). These studies indicate that, like cancer cells, PKD cells require high levels of 
glucose - the principal source of energy of the cells - and reprogram their metabolism to 
use aerobic glycolysis (known as the Warburg effect) for energy production. This 
metabolic switch leads to enhanced glucose metabolism and uncontrolled cell proliferation. 
Considering the slow progression of PKD in humans and the late onset of therapeutic 
treatments, the proven enhanced effect of 2DG in slowly progressive murine PKD model 
(Chiaravalli et al., 2016) makes this compound a compelling therapeutic agent, even 
though it is not currently approved for treating any human condition. Hence, our results, 
together with existing evidence from in vivo studies, confirm 2DG clinical potential in the 
treatment of PKD and encourage its use and efficacy evaluation in clinical trials.   
Previous investigations indicate that berberine exerts anti-proliferative effects in different 
cancer cell lines (Iizuka et al., 2000) and PKD cells (Bonon et al., 2013).  
Iizuka et al. reported that berberine causes cancer cell accumulation in G0/G1 phase and a 
relative reduction of the S phase (Iizuka et al., 2000). Bonon et al. demonstrated that 
berberine treatment of human and mouse PKD cystic cell lines reduces cell proliferation by 
increasing G0/G1 phase and inhibiting both phosphorylation of the extracellular signal-
regulated kinase (ERK) - which stimulates cell proliferation (Yamaguchi et al., 2003) - and 
activity of p70-S6 kinase, a downstream effector of mTOR (Bonon et al., 2013).  
Moreover, berberine is able to increase intracellular levels of reactive oxygen species by 
altering mitochondrial membrane potential, leading to mitochondrial collapse and 
compromising oxidative phosphorylation process. Being able to interact with the adenine 
nucleotide translocator, berberine causes ATP depletion in cancer cells (Diogo et al., 
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2011). Moreover, because of its chemical structure that resembles that of intercalating 
agents, berberine can directly bind to DNA (Krey and Hahn, 1969), eliciting double-strand 
breaks, eventually leading to cell death for apoptosis (Zhu et al., 2014). Overall, these 
properties may justify the effects of berberine in our system. By demonstrating the potent 
effect of this compound on cyst regression, as well as on tubular lumen and epithelial 
architecture restoration, we highlighted the hitherto unknown therapeutic potential of 
berberine for the treatment of PKD. 
Important issues affect the study of the mechanisms of renal epithelial tubulogenesis and 
UB branching in human tissues. The first is the scarcity of suitable human embryonic 
material. The second is the lack of systems that, starting from single cells, allow 
engineering UB capable of recapitulating morphogenetic events occurring during early 
organogenesis. These problems are also present when studying human developmental 
disorders, as there is lack of methods for engineering in vitro kidney tissue from patients 
carrying genetic mutations. 
To deal with these problems, we tested our engineering system for its ability to efficiently 
provide human kidney tubules from hiPSCs. To this end, we differentiated hiPSCs into 
UB-committed renal progenitor-like cells using a robust protocol based on brief exposure 
to defined growth factors (Xia et al., 2013), and then directed them to grow within PDMS 
scaffolds under tubulogenic conditions, as we did with MDCK cells. Like MDCK cells, 
human cells generated seemingly compact tubular structures, but HGF stimulation alone 
was not enough to induce the formation of a monolayered epithelium surrounding a 
continuous lumen. To achieve such architectural arrangement it was necessary to add 
GDNF to the medium, which indicates that GDNF exerts an essential signalling role in the 
maturation of hiPSC-derived UB tubular structures. This reflects the utmost importance of 
the GDNF for UB formation and growth during early kidney development in vivo. Hence, 
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we successfully engineered human UB-like branched tubular structures endowed with a 
single lumen bounded by a monolayered epithelium. The engineered human tubules were 
capable of synthetic macromolecule internalisation and OAT-mediated anion tracer 
transport, both maturation features typical of in vitro cultured UBs (Sweet et al., 2006; 
Meyer et al., 2004; Lawrence et al., 2015). Of note, these findings are unprecedented in 
stem cell-derived kidney tissues.  
When engineered human tubules were co-cultured with mouse embryonic kidneys in a 3D 
collagen culture system, they responded to kidney developmental cues by forming primary 
and secondary buds. These findings clearly demonstrate that our UB-like tubules are able 
to recapitulate early steps of UB morphogenesis and highlight the usefulness of our system 
for studying mechanisms of human kidney development.  
Previous in vitro tubulogenesis systems using rodent kidney cell lines or isolated UBs, 
revealed that distinct growth factors are indispensable for regulating UB growth and 
branching morphogenesis within a 3D ECM environment (Qiao et al., 1999a, 1999b, 2001; 
Sakurai et al., 1997; Steer and Nigam, 2004). In our 3D collagen culture system, we 
identified a novel combination of growth factors that allows the engineered human UB-like 
tubules to undergo budding morphogenesis to an extent akin to that obtained with mouse 
embryonic kidney co-culture.  
Although a higher degree of tubule maturation needs to be reached and a number of UB 
functions must be still tested, our data suggest that the engineered human tubules can be 
employed for studying human development and modelling diseases arising from or 
affecting the collecting duct system. 
In a similar set of experiments, we used the system to disclose and quantify possible 
morphogenetic defects in tubules engineered with hiPSCs derived from a patient carrying a 
heterozygous PAX2 mutation, and previously diagnosed with focal segmental 
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glomerulosclerosis (FSGS) (Barua et al., 2014). In developing kidney, PAX2 gene is 
expressed in branching UB, collecting duct epithelia and early nephrons (Dressler et al., 
1990; Dressler and Woolf, 1999). FSGS is a rare CKD that affects glomeruli. This 
condition arises when podocytes are targeted by cellular stresses to which they respond 
through cytoskeletal reorganisation, leading to foot-processes effacement. In case of long-
lasting harmful stressors, podocytes reach critical injury levels causing their irreversible 
detachment from the GBM and the underlying glomerular capillaries’ sclerosis due to 
plentiful matrix accumulation (D’Agati et al., 2011). Therefore, pivotal in the FSGS 
pathogenesis is podocyte damage and loss (D’Agati et al., 2011).  
However, our findings suggest that the podocytes’ attrition typical of FSGS may occur 
secondary to kidney developmental anomalies associated with UB morphogenesis. We 
observed that the patient-derived UB-like tubules’ budding ability was significantly lower 
than that of healthy donor-derived tubules. This suggests that PAX2 mutations, such as the 
one we studied here, may be contributing to the defective UB arborisation and, ultimately, 
to a reduction in nephron number. This is supported by data from heterozygous Pax2 
mutant mice showing diminished UB branching during fetal kidney development, 
associated with a marked decrease in nephron number at birth (Dziarmaga et al., 2006). As 
the amount of UB branching events determines the definitive number of nephrons (Nigam 
and Shah, 2009; Nagalakshmi and Yu, 2015), the patient’s kidneys may have had a 
reduced UB arborisation during early developmental stages, which led to suboptimal 
nephron endowment. It is also conceivable that the patient’s pathological lesions may have 
arisen as a consequence of haemodynamic stresses, which accelerated podocyte 
impairment by acting on nephrons reduced in number. 
Although additional studies are necessary to validate these hypotheses, our findings 
provide new insights in understanding the pathogenesis of FSGS and confirm the 
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usefulness of our system to investigate individual patient's genetic disorders, for which no 
models currently exist.  
By directing hPSC in vitro differentiation, other groups created rudimental 3D human 
kidney organoids in a dish (Taguchi et al., 2014; Morizane et al., 2015; Freedman et al., 
2015; Takasato et al., 2015). Yet, the complete lack of UB (Taguchi et al., 2014; Freedman 
et al., 2015; Morizane et al., 2015) or otherwise its formation as multiple, individual small 
ducts (Takasato et al., 2015; Xinaris et al., 2016) impeded establishment of the proper 
kidney tissue patterning and cortical-medullary orientation, which would normally be 
imposed by a single collecting duct tree. These developmental insufficiencies may 
probably account for severe anatomical malformations within the organoids, that is the 
establishment of nephron-nephron connections and multi-branched nephrons (Freedman et 
al., 2015; Morizane et al., 2015; Takasato et al., 2015). Overall, these anomalies indicate 
that such approaches cannot accurately replicate kidney organogenesis in vitro. 
In terms of kidney organoid function, there would also be a serious limitation arising from 
the above-mentioned developmental insufficiencies. Indeed, as the urine produced by 
nephrons should be drained away via a single collecting duct tree, the absence of UB or the 
lack of connections among the multitude of collecting ducts would impede the 
accomplishment of this vital function.  
Our innovative technology may prove extremely useful to overcome all these problems, as 
it allows engineering hiPSC-derived UB-like tubular units with developmental capacities, 
which could be physically combined and reciprocally interact with hiPSC-derived MM cell 
aggregates, giving rise to functional human kidney organoids arranged organotypically 
around a single collecting duct tree. Constructing functional organoids from hiPSCs, which 
can be directly derived from patients’ own somatic cells, will facilitate the establishment of 
systems for in vitro disease modelling, personalised therapies, toxicology and 
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developmental studies, and may offer solid foundation for regenerative medicine 
applications.  
 
To summarise, we have developed a 3D culture system that produces functional epithelial 
tubules of predetermined geometries starting from dispersed epithelial cells. Tubules 
engineered using the renal epithelial cell line are able to accurately replicate the PKD 
phenotype and respond to pharmacological treatments in a quantifiable manner. It 
demonstrates that these tissues can provide a pioneering tool for studying renal 
pathophysiology in vitro and conducting pharmacological studies. Importantly, our system 
can efficiently produce human UB-like tubules able to exert kidney-specific functions, 
endowed with developmental capacities, and suitable to investigate mechanisms of normal 
kidney development as well as possible aetiological roles of genetic alterations in UB 
morphogenesis and disease. 
Although culture conditions for other cell types have yet to be defined, our technology is 
applicable and can be ideally adapted, with only minor modifications, to engineer different 
kinds of tissue, such as branched endothelial and lung epithelia. These may in turn be used 
to study human vascular and pulmonary developmental and pathophysiological 
mechanisms, respectively.  
Overall, this controlled experimental system provides an accurate, rapid, cost-effective and 
reproducible methodology with which to model kidney disease, screen drugs and study 
development. It may represent an attractive and promising platform from which the 
spatially and geometrically controlled engineering of human kidney tissue with realistic 
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Figure 1. Schematic diagram of kidney development and nephron formation. 
Metanephric kidney development begins when ureteric bud (UB) emerges as a swelling of 
the caudal nephric duct (ND) and invades the metanephric mesenchyme (MM) of the 
posterior nephric cord (NC). Reciprocal autocrine and paracrine interactions between UB 
and MM induce the UB to first undergo bifurcated branching to form a T-shaped bud 
consisting of two tips and a stalk. Hereafter, each UB tip undergoes multiple rounds of 
bifurcation (branching morphogenesis) giving rise to the tree-like collecting duct system, 
whereas the elongated UB stalk forms the ureter. In turn, the branching UB epithelium 
induces nephrogenesis by promoting condensation of a subset of nephron progenitor cells 
within the MM around each UB tip. Condensed cells form the cap mesenchyme (CM), 
which epithelialise to form the renal vesicle (RV), the first epithelial structure of the 
nephron. The RV further grows and progressively forms comma- and S-shaped bodies 
(SSB), which eventually develop into mature nephrons. The distal end of the SSB fuses 
with a UB tip to form a continous lumen, giving rise to the distal tubule of the nephron. 
The MM contains another cell population, the renal interstitial (RI) cells - also known as 
renal stromal cells. These cells support nephrogenesis and UB branching, and are the 
precursors of renal interstitial fibroblasts, vascular smooth muscle cells, pericytes and 
mesangial cells. Kidneys are subdivided into two main regions: the cortex (C) and the 
medulla (M), each containing different segments of nephron and UB/collecting duct 
tubular epithelia. Adapted from (Nagalakshmi and Yu, 2015). Copyright 2015 by the John 
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Figure 2. Kidney anatomy. Schematic cross section of the kidney showing the overall 
internal structure and the main anatomical components of the organ. Adapted from 
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Figure 3. Nephron anatomy and collecting duct cortical-medullary orientation. 
Schematic illustration of a nephron and spatial distribution of mature glomerulus and renal 
epithelial tubular structures (proximal convoluted tubule, loop of Henle, distal convoluted 
tubule and collecting tubule) along the kidney cortical-medullary axis. Note the clear 
distinction between cortical and medullary regions. Arrows indicate the ultrafiltrate (urine) 
flow direction. Adapted from Beltina.org - Encyclopedia of Health (2011). Source: 
http://www.beltina.org/health-dictionary/nephron-function-kidney-definition.html. Image 
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Figure 4. Historical summary of 3D kidney tissue engineering approaches. The main 
themes and technologies concerning kidney organ generation are listed in chronological 
order. Tissue-based approaches (blue); embryonic kidney cell- and cell line-based 




























  CHAPTER 5 – FIGURES AND LEGENDS 
96 
 
Figure 5. Engineering tubular structures starting from MDCK cell suspensions. (a) 
Schematic workflow for PDMS scaffold fabrication. Based on the custom-designed 
patterns, plastic masters are 3D-printed using rapid prototyping technologies and then 
utilised to produce the scaffolds through PDMS replica moulding and polymerisation. (b) 
Experimental design: MDCK cells are centrifuged, resuspended in collagen I, seeded into 
the PDMS scaffold cavity and cultured in the presence of HGF for up to 2 days. (c) 
Immediately after seeding (day 0), the mixture of collagen and cells completely fills the 
scaffold cavity. At day 1, cells organise to form tubular aggregates corresponding to the 
shape of the cavity and showing marked shrinkage. At day 2, branches of the shrunk 
tubular structures emerge from the cavities, and a translucent area (middle panel, asterisk) 
delimited by darker edges (middle panel, arrows) is visible through bright-field 
microscopy. (d) Ramified and (e) tree-like tubular structures after 2 days of culture. (f) A 
multichannel scaffold containing epithelial microtubules after 2 days of culture. Scale bars: 
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Figure 6. Engineered tubules display lumen formation, epithelial absorption of 
molecules and transport of ions at 2 days. (a) Confocal Z-stack imaging from the surface 
to the inner region of a microtubule demonstrates the formation of a continous lumen (L) 
in the central region. E-cadherin (red) is expressed by peripheral cells of the microtubule. 
(b) A branch from a macrotubular system showing an extended lumen (L) enclosed by a 
monolayered epithelium of cells with aligned nuclei and expressing E-cadherin (red) and 
WGA-lectin (green) in the lateral and basal membranes, respectively (inset). (c-e) 
Microtubules displaying (c) dextran (green) internalisation and (d) 6CF (green) anion 
transport in the absence or (e) presence of the organic anion transporter inhibitor 
probenecid. WGA-lectin, wheat-germ agglutinin-lectin; 6CF, 6-carboxyfluorescein; DAPI, 
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Figure 7. MDCK-derived tubules model PKD and respond to the treatment with 
different compounds. (a) Schematic representation of 3D collagen culture system. After 2 
days of culture, engineered microtubules are harvested from the scaffold, embedded in 
collagen I, stimulated with forskolin for 7 days to induce cyst formation and then treated 
with different compounds to evaluate cyst regression. (b) Bright-field image of a forskolin-
stimulated microtubule showing many large spheroidal cysts stained with hematoxylin and 
eosin (insets). (c, d) Cysts are delimited by a monolayered epithelium of cells positive for 
E-cadherin (white) in the basolateral membranes and (d) podocalyxin (green) in the apical 
membranes (insets). The tubular lumen is lost. (e-j) Forskolin-stimulated tubules after a 7-
day treatment with (e) rapamycin, (f) Tolvaptan in combination with AVP, (g) OCTR, (h) 
PAS, (i) 2DG or (j) berberine. (i, j) 2DG and berberine treatments restore tubular lumen. 
(k, l) Quantification of cyst number/mm
2
: No treatment (forskolin; 1205 ± 48.81); 
rapamycin (990 ± 174.5); OCTR (508.5 ± 39.52); PAS (688.9 ± 52.1); 2DG (348.1 ± 
44.15); berberine (335.8 ± 27.93); AVP (1948 ± 283.4); AVP+Tolvaptan (716.4 ± 57). Data 
are expressed as means ± s.e.m. from three independent experiments. (k) Number of fields 
analysed: n=18 for forskolin, n=6 for rapamycin, n=6 for OCTR, n=7 for PAS, n=8 for 
2DG, n=11 for berberine. *P<0.05 versus PAS, °P<0.0001 versus rapamycin, #P<0.0001 
versus forskolin by one-way ANOVA with Tukey’s multiple comparisons test. (l) Number 
of fields analysed: n=4 for AVP, n=9 for Tolvaptan in combination with AVP. **P<0.0001 
by two-tailed Student’s t-test. DAPI, blue-stained nuclei; AVP, arginine vasopressin; 
OCTR, octreotide; PAS, pasireotide; 2DG, 2-deoxy-D-glucose. Scale bars: 100 m (b), 50 
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Figure 8. Engineering functional human UB-like tubules using iPSCs. (a) Experimental 
design. Human iPSCs are differentiated toward UB-like progenitor cells. Cells from 
differentiation days 3 and 4 are pelleted and then re-suspended in collagen I, seeded into 
the PDMS scaffold cavity, and cultured in the presence of HGF and GDNF for 2 days. (b) 
A branch from a macrotubule engineered with cells from differentiation day 3 displaying a 
continous lumen (L) enclosed by a monolayer of E-cadherin (white) and WGA-lectin 
(green) positive cells. Inset: cells of the tubular wall show aligned nuclei (blue), and E-
cadherin (white) and WGA-lectin (green) in the basolateral membranes. (c) Z-stack images 
of a microtubule engineered with cells from differentiation day 4 show the presence of a 
single central lumen (L) lined by a WGA-lectin-positive (red) epithelium. (d, e) 
Microtubules showing (d) dextran (green) internalisation and (e) 6CF (green) transport. 
UB, ureteric bud; d, day; WGA-lectin, wheat germ agglutinin-lectin; DAPI, blue-stained 
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Figure 9. Engineered tubules as a tool for studying human UB developmental 
processes and defects. (a) Experimental design. Fragments of hiPSC-derived 
macrotubules are transferred from the PDMS scaffold to the 3D collagen culture system 
and cultured with mouse embryonic kidneys or in the presence of different combinations of 
growth factors for up to 2 days. (b, c) Healthy donor-derived tubule co-cultured with 
mouse embryonic kidneys. (b) At day 1, long primary buds emerge (left panel). At day 2, a 
lateral ramification (arrow) arises from the primary bud. (c) A ramified bud consists of 
aligned E-cadherin-positive cells with linearly oriented nuclei. (d) Percentage of the 
ramified buds in the total buds emerged from healthy donor-derived tubules. Data are 
expressed as means ± s.e.m. from three independent experiments. Number of fields 
analysed: n=48 for H+G, n=30 for H+G+F1 and H+G+F7, n=22 for H+G+F1+F7, n=21 
for mouse embryonic kidneys.  *P<0.05 versus H+G, °P<0.05 versus H+G+F1, #P<0.01 
versus H+G by one-way ANOVA with Holm-Sidak’s multiple comparisons test. (e, f) A 
healthy donor-derived tubule cultured with the complete combination of growth factors 
displays primary and secondary buds (arrows) some of which showing terminal bifid 
branching (asterisks). (f) A primary bud arising from healthy donor-derived tubule cultured 
as that in (e). (g) Percentage of the ramified buds in the total buds emerged in healthy 
donor- and patient-derived tubules cultured with all growth factors. Data are expressed as 
means ± s.e.m. from three independent experiments. Number of fields analysed: n=22 for 
healthy donor- and n=27 for patient-derived tubules. **P<0.0005 by two-tailed Student’s t-
test. (h, i) Patient-derived tubule cultured with all growth factors develops mainly primary 
buds. (i) A primary bud arising from patient-derived tubule cultured as that in (h). DAPI, 
blue-stained nuclei; H, HGF; G, GDNF; F1, FGF1; F7, FGF7. Scale bars: 100 m (b, left 
panel; e, left panel), 50 m (e, right panel; h), 20 m (b, right panel; c, f, i). 
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Supplementary Figure 1. PDMS scaffold design and fabrication. (a-d) Patterns 
designed for PDMS scaffold fabrication. Related lengths, depths, widths and angles are 
indicated for each pattern. Designed geometries: (a) linear, (b) bifurcated with an 80° 
terminal bifid branch, (c) asymmetrical with two 30° lateral branches arising from the 





the amplitude of first and second branching generation, respectively; L refers to central 
trunk length; n is the order of branching generation, and =1.618 is the ‘golden ratio’. (f) 
The tree-like pattern consisting of fractal-like planar ramifications with different lengths 




=130° and n=3. (g) Linear 
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Supplementary Figure 2. Effect of cell densities on tubule formation. (a, b) Cell 
concentrations lower than those established as optimal completely prevent tubular structure 
formation both (a) in macro- and (b) in micro-scaffolds. (c) Three hours after seeding at 
the optimal cell concentration, MDCK cells organise to form a tube-shaped aggregate. 
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Supplementary Figure 3. MDCK cell-derived tubules display polarised epithelium 
establishment and apoptosis during lumen formation. (a) At day 2, the monolayered 
epithelium forming the tubular wall is double positive for PNA-lectin (red) and 
podocalyxin (green) in the apical domains. (b) At day 1, macrotubules develop a major 
luminal space (L) bounded by aggregates of cells with condensed chromatin (inset, 
asterisks). (c) Cells forming the aggregates in the central areas of tubule display nuclear 
fragmentation and are positive for the apoptotic marker cleaved caspase 3 (red). (d) At day 
2, tubular structures formed in the absence of HGF do not develop a single central lumen. 
PNA-lectin, peanut agglutinin-lectin; WGA-lectin, wheat germ agglutinin-lectin; DAPI, 
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Supplementary Figure 4. Gene expression profile of human iPSCs during 
differentiation into UB-like progenitor cells. NANOG (pluripotency marker) expression 
decreases progressively. T (Brachyury) (mesendoderm marker) expression peaks at d2, 
while LHX1 (LIM1) (intermediate mesoderm marker) and GATA3 (ureteric epithelium 
marker) peak at d3. PAX2 (nephric lineage marker) and HOXB7 (UB-related transcription 
factor) expression levels increase progressively up to d4. Values are relative to the 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data shown are 
from one representative experiment of three independent experiments. d, day; NANOG, 
Nanog homeobox; T, brachyury transcription factor; LHX1, LIM homeobox 1; GATA3, 
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Supplementary Figure 5. GDNF is indispensable for lumen formation in human UB-
like tubules engineered with 3- and 4-day differentiated iPSCs. (a) Tubular structure 
engineered using 3-day differentiated hiPSCs cultured for 2 days in the presence of HGF 
alone fails to develop a single lumen. (b) Tubular structure engineered using 3-day 
differentiated hiPSCs exposed to both HGF and GDNF displays a lumen (L) and some 
cells in the tubular wall positive for PKC- (red) in the apical domains, indicating the 
establishment of epithelial polarisation. (c) Undifferentiated hiPSCs proliferate massively 
within the scaffold cavity and appear scattered throughout the culture medium. (d) hiPSCs 
from differentiation day 2 form large and filamentous cell aggregates that detach from the 
mould and fail to form tubules. (e) At day 1, a macrotubule cultured in the presence of 
HGF and GDNF displays multiple lumens (L) surrounded by apoptotic cells with 
condensed chromatin (inset, asterisks). (f) The same cells that show chromatin 
condensation also express the apoptosis marker cleaved caspase 3 (red) and display nuclear 
fragmentation. PKC-, protein kinase C isoform-zeta; DAPI, blue-stained nuclei. Scale 
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Supplementary Fig. 6. Differentiation of healthy donor-derived iPSCs toward UB-like 
progenitor cells and tubule engineering. (a) Gene expression profile of healthy donor-
derived iPSCs during differentiation. NANOG expression decreases up to d4, while T 
(Brachyury) peaks at d2. LHX1 (LIM1) and GATA3 peak at d3, while PAX2 and HOXB7 
expression levels increase up to d4. Values are relative to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data shown are from one 
representative experiment of three independent experiments. (b) Z-stack images of healthy 
donor-derived microtubule display formation of a single lumen (L) in the tubular central 
region. (c) Healthy donor-derived microtubule showing a continous lumen (L) lined by a 
monolayered epithelium positive for (c, inset) PKC- (red) in the apical membranes. d, 
day; NANOG, Nanog homeobox; T, brachyury transcription factor; LHX1, LIM homeobox 
1; PAX2, paired box 2; GATA3, GATA binding protein 3; HOXB7, homeobox B7; WGA-
lectin, wheat-germ agglutinin lectin; PKC-, protein kinase C isoform-zeta; DAPI, blue-
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Supplementary Figure 7. Characterisation of patient-derived iPSCs. (a) Patient-
derived iPSCs are positive for the pluripotency markers OCT4, TRA-1-60, NANOG, TRA-
1-81, SSEA3 and SSEA4. (b) The pluripotency genes’ expression level in patient-derived 
iPSCs is similar to that in human embryonic stem cell line H9, used as control. Data are 
expressed as means ± s.e.m. from three independent experiments. (c) Patient-derived iPSC 
in vitro differentiation into all three germ layers through EBs formation: -Tubulin III 
(ectoderm marker), -SMA (mesoderm marker) and GATA4 (endoderm marker). (d) 
Karyotype analysis revealing normal 46,XY chromosomal number and structure. TRA-1-
60, Tumour-related antigen-1-60; NANOG, Nanog homeobox; TRA-1-81, Tumour-related 
antigen-1-81; SSEA3, Stage-specific embryonic antigen 3; SSEA4, Stage-specific 
embryonic antigen 4; SOX2, SRY-box2: -SMA, alpha-smooth muscle actin; GATA4, 
GATA binding protein 4; EBs, Embryoid bodies; DAPI, blue-stained nuclei. Scale bars: 50 
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Supplementary Figure 8. Differentiation of patient-derived iPSCs toward UB-like 
progenitor cells and tubule engineering. (a) Gene expression profile of patient-derived 
iPSCs during differentiation. NANOG expression decreases up to d4, while T (Brachyury) 
peaks at d2. LHX1 (LIM1), PAX2, GATA3 and HOXB7 expression levels increase up to d4. 
Values are relative to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Data shown are from one representative experiment of three independent 
experiments. (b) Patient-derived macrotubule after 2 days of culture shows marked 
shrinkage and develops a continuous lumen (L) lined by a monolayered epithelium of 
aligned cells positive for E-cadherin in the basolateral membranes (inset). d, day; NANOG, 
Nanog homeobox; T, brachyury transcription factor; LHX1, LIM homeobox 1; PAX2, 
paired box 2; GATA3, GATA binding protein 3; HOXB7, homeobox B7; WGA-lectin, 
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